Department of Health & Human Services Public
Health Service
Food
and Drug Administration
Memorandum Center
for Biologics Evaluation and Research
1401
Rockville Pike
Division of Clinical Trial Design and Analysis
HFM-582
Date:
Advisory Committee Meeting
Clinical Review Briefing Document
STN 103795 / 5123
Etanercept for the Treatment of Ankylosing Spondylitis
Applicant: Immunex, Inc.
TABLE OF CONTENTS
The purpose of this meeting is to present to the Arthritis Advisory Committee data submitted in support of a claim for the use of ENbrel® (Etanercept) for the treatment of adult patients with Ankylosing Spondylitis (AS) and to discuss issues related to the measurement of clinical efficacy in this disorder.
Filing of Application
On
Study Products
Etanercept 25 mg administered subcutaneously(SC) twice per week supplied to the pharmacies as a sterile lyophilized powder in vials containing 25 mg of etanercept, 40mg mannitol USP, 10mg sucrose, NF and 1.2 mg TRIS USP
Placebo also administered SC twice per week was supplied in vials identical to above but without the etanercept.
Ankylosing Spondylitis and
its Treatment
Ankylosing spondylitis is a chronic inflammatory rheumatic disease of unknown etiology associated with HLA-B27. It affects primarily the sacroiliac joints and the axial skeleton, although peripheral joint involvement may also be an important feature. Common clinical manifestations include lower back pain and stiffness, chest pain, extra-articular tenderness due to enthesitis (an inflammatory reaction at the site of insertion of tendon into bone) and joint pain and effusion. Extraskeletal manifestations are seen in some patients, including uveitis, aortic incompetence, cardiac conduction abnormalities and lung fibrosis. Ankylosing spondylitis belongs to a group of rheumatic disorders, termed spondylarthropathies, that also includes Reiter’s syndrome/reactive arthritis, the arthropathy of inflammatory bowel disease, psoriatic arthritis and undifferentiated spondyloarthropathies. Symptoms of ankylosing spondylitis are usually manifest by late adolescence or early adulthood. The course of disease is highly variable. While it is often self-limited, it may remain active over many years. Work disability has been observed in up to 15% of patients after 10 years of disease and in up to 45% of patients after 20 years of disease (Guillemin F, Briancon S et al. Arthritis Rheum 33:1001, 1990). While medications have not been demonstrated to reduce the rate of disability, a number of other interventions have been hypothesized to affect the progression of disability, including physiotherapy, vocational counseling and job training.
Approximately 350,000 patients in
the United States have been diagnosed with AS. A variety of non-steroidal
anti-inflammatory drugs (NSAIDS) are approved for treatment of signs and
symptoms of AS. Certain drugs which are considered disease-modifying drugs
(DMARDS) in rheumatoid arthritis (RA) such as Sulfasalazine or Methotrexate are
used by some clinicians in AS but none are FDA approved for this use There are
no data from randomized controlled clinical trials to support clinical benefit
for DMARDS in AS.
Tumor necrosis factor (TNF)
levels have been shown to be elevated in serum and synovial tissue of patients
with AS. These findings provide a rationale for the study of the TNF blocking
agent etanercept to reduce the clinical signs and symptoms of AS.
Etanercept has been approved for the treatment of Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis and Psoriatic Arthritis based upon randomized controlled trials that have shown safety and efficacy. Since AS may share pathogenic mechanisms with these disorders, efficacy for etanercept in these other disorders supports the rationale to study etanercept in AS.
Development of Efficacy
Endpoints for Clinical Trials
Derivation of the ASAS Response Criteria
One of the difficulties encountered by investigators seeking to demonstrate benefit of various therapeutic modalities has been the lack of a outcome assessment similar to the ACR 20 used in Rheumatoid Arthritis to assess short-term benefit of therapies in this chronic disease. Over the years a number of questionnaire based instruments have been developed including the Bath Ankylosing Spondylitis Functional Index (BASFI) which measures the physical function impairment caused by AS, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses upon signs and symptoms of the inflammatory aspects of AS, nocturnal and total back pain, the patient’s global assessment and actual physical measurements of spinal mobility such as the Schober’s test, chest expansion score and Occiput to wall measurement. The Assessments in Ankylosing Spondylitis (ASAS) Working Group developed and published a core set of 5 domains whose evaluation were deemed essential in the evaluation of the therapeutic efficacy. These domains were: physical function, pain, spinal mobility, spinal stiffness/inflammation and patient’s global assessment. In 2001, the ASAS Working Group published the ASAS Response Criteria based upon analysis of 5 randomized trials of NSAIDS in AS which enrolled 1030 patients for £ 6 weeks of treatment. Four of the five necessary domains were included in the Response Criteria since in these placebo response rates were low and using these response criteria effectively differentiated drug effect from placebo. The remaining domain, spinal mobility was omitted from the Response Criteria because of a lack of responsiveness possibly owing to the lack of effect of NSAIDS on spinal mobility as well as the short duration of treatment.
The ASAS Working Group Response Criteria were used in both Phase 3 studies in this application, and were compared with pre-specified response criteria used in the phase 2 study.
Clinical Studies of
Etanercept for Ankylosing Spondylitis
The studies of etanercept in AS are summarized in (Table 1)
Table 1 Clinical Studies of
Etanercept 25mg biw for Ankylosing Spondylitis
Protocol No. Study Objectives |
Treatment Duration N |
Treatment Groups |
016.0026 Phase 2 Efficacy and safety |
16 weeks 20 |
Etanercept 25mg sc biw |
16 weeks 20 |
Placebo sc biw |
|
016.0037 Phase 3 Efficacy, safety, PK |
24 weeks 138 |
Etanercept 25mg sc biw |
24 weeks 139 |
Placebo sc biw |
|
47687 Phase 3 Efficacy and safety |
12 weeks 45 |
Etanercept 25mg sc biw |
12 weeks 39 |
Placebo sc biw |
Including patients participating in the phase 2 study and the two phase 3 studies to be discussed, a total of 203 patients with active Ankylosing Spondylitis have received etanercept at 25mg sc biw for a duration of between 12 and 24 weeks during the conduct of this clinical development (Table 1).
Etanercept (Enbrel) is a dimeric fusion protein consisting of the human p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1. It binds specifically to TNF and blocks its interaction with cell surface TNF receptors. It is approved for treatment of moderately to severely active rheumatoid arthritis and for treatment of active arthritis in patients with psoriatic arthritis. Etanercept is approved as monotherapy or in combination with methotrexate for patients who do not respond adequately to methotrexate alone. It has been shown to reduce signs and symptoms in rheumatoid arthritis and to inhibit the progression of structural damage. It is also approved for treatment of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more DMARDs.
The safety of etanercept has been studied in clinical trials of approximately 1200 patients with RA, followed for up to 36 months and in 157 patients with psoriatic arthritis for 6 months. In addition, over 100,000 patients have been exposed to the marketed product. Serious adverse events are observed infrequently with etanercept and include serious infections and sepsis, demyelinating syndromes and lupus-like syndrome. A recent FDA analysis of the clinical trial data with etanercept, infliximab and adalimumab suggested that use of TNF-blocking agents may be associated with a higher risk of lymphoma. For etanercept, the rate of lymphoma was 2-fold higher than that expected in the general population. However, patients with rheumatoid arthritis, particularly those with highly active disease, may be at a higher risk for the development of lymphoma.
The phase 2 Study 160026 was a randomized, double-blind, placebo controlled trial designed to explore the clinical efficacy of etanercept in controlling disease activity of AS in conjunction with the use of standard medication for AS. Eligible patients were randomized 1:1 to receive either etanercept 25 mg biw or placebo biw. Duration of the trial was 16 weeks with 4 weeks of safety follow-up. This trial commenced in 1999 prior to the publishing of the ASAS Working Group Response Criteria and utilizes a somewhat different set of Clinical Response Criteria that comprised the Bath Ankylosing Spondylitis Functional Index (BASFI), Nocturnal back pain Visual Analogue Scale (VAS), Patient Global Assessment VAS, Duration of Morning Stiffness and Swollen Joint Score. analysis using the pre-specified endpoint indicated increased response rate associated with etanercept treatment. In addition, an ad hoc analysis using the ASAS Working Group Response Criteria was performed and it also showed increase in response incidence with etanercept treatment. This study will be reviewed further later in this document
Rationale for Selection of
Etanercept Dosage for Phase 3
Etanercept at a dose of 25 mg
administered SC twice weekly was selected for this study
based on clinical trials in
patients with RA and psoriatic arthritis, which have
shown this to be an effective
dose, and because this dose appeared to provide benefit in
the earlier Phase 2 trial in
patients with AS ~xr241i
~xr242i
Study Title
“ Multicenter, double-blind, Placebo-controlled, Randomized Phase 3 Study of Etanercept (ENBREL®) in the Treatment of Patients with Ankylosing Spondylitis”
Study Design
Study 016.0037 was a randomized, multicenter, international, double blinded, placebo-controlled phase 3 study of etanercept versus placebo in 277 patients with active ankylosing spondylitis. Subjects were randomly assigned to one of two treatment arms: etanercept 25mg sc biw or placebo on a 1:1 basis. Subjects were treated for a total of 24 weeks with the primary efficacy endpoint determined at week 12 and a conditional primary efficacy endpoint determined at week 24 if efficacy was demonstrated at week 12. There were 4 weeks of safety follow-up after the 24 weeks of study treatment. Randomization was stratified for the presence of DMARDS approved for use in the study. These were Sulfasalazine, Methotrexate and Hydroxychloroquine.
Dosing and Dosing Modification
Etanercept 25 mg or placebo was administered sc twice per week for 24 weeks in patients with active AS who met eligibility criteria. There was no provision for dose modification of study drug. Patients who developed a Grade 3 or 4 adverse event thought to be related to study treatment could suspend study drug for one week but if 4 consecutive doses of study drug were missed, the subject was withdrawn from the study. In this situation, the subject was considered to be a treatment non-responder for efficacy and would continue for an additional 30 days for safety analysis.
Study Population
Men and women, outpatients, between 18 and 70 years of age with AS, as defined by the modified New York Criteria for Ankylosing Spondylitis (Table 60 Appendix A) which was active at the time of enrollment as defined by:
- visual analog
scale (VAS) values ³ 30 (on a scale of 0–100) for the following
parameter:
- Average of
duration and intensity of morning stiffness
PLUS VAS values ³ 30
for 2 of the following 3 parameters:
- patient global
assessment
- average of VAS
values for nocturnal back pain and total back pain
- average of 10
questions on the BASFI.
Excluded were subjects with:
Complete Ankylosis of the spine
use of DMARDS other than Sulfasalazine, Methotrexate, or Hydroxychloroquine
Previous Receipt of Etanercept or other TNFa-blocking agents
Dose of prednisone > 10mg/d or changed within 2 weeks of baseline evaluation
Dose of NSAIDS changed within 2 weeks of baseline
Primary Efficacy Outcome
The primary efficacy outcome was determined at 12 weeks of treatment using the following ASAS Response Criteria
ASAS Response Criteria (ASAS 20) at 12 weeks defined as follows:
· Function represented by BASFI average of 10 questions
regarding ability to perform specific tasks as measured by VAS with extremes
labeled “easy” and “impossible.” (Table
62 Appendix C)
Secondary Efficacy Outcomes:
Secondary
Efficacy Outcomes included:
· the ASAS Response Criteria of 50% and 70% improvement
at weeks 12 and 24 which were calculated as follows:
- The ASAS 50
response was to be computed and analyzed using rules similar to those defined
for the ASAS 20 response criteria, except that a 50% improvement was required
for 3 of the 4 components, in addition to a ³ 10
point absolute improvement in the change scores for 3 of the 4 components. The
deterioration criteria were to be defined exactly as for the ASAS 20 response
criteria (worsening of 20% or more and absolute worsening of ³10 points).
- The ASAS 70
response was to be computed and analyzed using rules similar to those defined
for the ASAS 50 response criteria, except that a 70% improvement was required.
-Additional
analysis of ASAS response at Weeks 12 and 24:
- Patients were to be classified
on 1–4 scale according to their highest response status with respect to ASAS
20, ASAS 50, and ASAS 70 endpoints.
- 1 = non-responder (did not achieve ASAS 20
response)
- 2 = ASAS 20
responder, but not ASAS 50 responder
- 3 = ASAS 50
responder, but not ASAS 70 responder
- 4 = ASAS 70
responder
Frequency
and time to the ASAS definition of partial remission defined as:
7i Value of < 20 (on a scale of
0–100) in each of the following 4 domains
-
Patient global assessment as determined by VAS.
- Pain
score (average of total back pain/nocturnal back pain) determined by VAS.
-
BASFI.
-
Average of responses to 2 questions regarding morning stiffness on the
6-question Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Additional
Outcome Measures:
In addition to the primary and
secondary endpoint analysis as listed above, additional outcome analysis was
performed using both the individual components of the ASAS Response Criteria as
well as Components of Other AS Instruments.
Individual
components of the ASAS Instrument
Components of Other AS Instruments
patients could be discontinued from study treatment for lack of efficacy defined as failure to improve 3 of 4 ASAS Response Criteria by 10% or more at week 8 (and 12) and at early termination visit. Such an individual would be considered an efficacy non-responder and would continue for 30 days for safety analysis only.
Statistical Analyses
Primary efficacy analysis
Secondary analyses:
All tests
were 2-sided, conducted at the a = 0.05 level.
Patients who
prematurely discontinued from study drug were considered non-responders for all
binary endpoints at time points after study drug discontinuation.
Major Protocol Amendments
Amendment 1: submitted approximately 6 weeks after the original protocol was approved this protocol increased the number of participating centers to 30 from 25 to insure rapid accrual, provided for a conditional primary endpoint defined by ASAS Response Criteria at Week 24 to be assessed if efficacy is established at Week 12, established that inclusion criteria were to be applied prior to randomization rather than enrollment, provided for Lack of Efficacy withdrawal at weeks 8, 12 and early termination visit rather than just after 12 weeks of treatment.
There were no additional
protocol amendments
Study Results
Study Centers
There were 28 participating study centers in US, Europe, and Canada. The majority of the subjects participated at North American Sites (78%)
Patient Disposition
330 patients were screened, 284 were randomized and 277 were randomized and received at least one dose of the study medication. Of the 46 individuals screened but not randomized, 40 were found to be ineligible, the remainder declined participation. Of the 7 individuals who were randomized but did not receive study medication, 4 had been randomized in error (did not meet inclusion criteria) and 3 withdrew consent prior to first dose. These 7 individuals were equally balanced across both study arms . Of the 277 individuals that were randomized and received study medication, 138 received etanercept and 139 received placebo. 96% of all participants completed 12 weeks of study, and 86% of placebo and 91% of etanercept recipients completed 24 weeks of participation. Adverse Events were the most common reason for withdrawal in the etanercept group (7 patients or 5%) and Lack of Efficacy most common reason in the placebo group (13 patients or 9%) (Table 2)
Table 2: Study Completion Status at 12 and 24 Weeks
|
Placebo |
Etanercept |
|
(N = 139) |
(N = 138) |
Patient Status |
n (%) |
n (%) |
Randomized but not dosed |
3/142 (2) |
4/142 (3) |
Completed 12 weeks in study |
134 (96) |
132 (96) |
Discontinued study (wks 0-12) due to: |
|
|
Adverse event |
0 |
4 (3) |
Lack of efficacy (LOE) |
2 (1) |
1 (1) |
Lost to follow-up |
0 |
1 (1) |
Patient refusal |
2 (1) |
0 |
Physician decision |
1 (1) |
0 |
Completed 24 weeks in study |
120 (86) |
126 (91) |
Discontinued study (wks 0-24) due to: |
|
|
Adverse event |
1 (1) |
7 (5) |
Lack of efficacy (LOE) |
13 (9) |
3 (2) |
Lost to follow-up |
1 (1) |
2 (1) |
Patient refusal |
2 (1) |
0 |
Physician decision |
2 (1) |
0 |
Table 3 Demographics 016.0037
|
Placebo |
Etanercept |
Characteristic |
N = 139 |
N = 138 |
Mean age in years |
41.9 |
42.1 |
Male (n [%]) |
105 (76) |
105 (76) |
Race (n [%]): |
|
|
Caucasian |
127 (91) |
130 (94) |
Hispanic |
6 (4) |
3 (2) |
Asian |
3 (2) |
3 (2) |
Native American |
3 (2) |
0 |
Black |
0 |
1 (1) |
Other |
0 |
1 (1) |
Mean weight (kg) |
83.1 |
82.2 |
Disease Characteristics at Baseline
Axial Disease
Characteristics
The mean duration of ankylosing spondylitis was similar in both arms at approximately 10 years. The percentage of HLA B-27 antigen positivity was identical at 84% in both arms and reflects the prevalence in the general patient population. Baseline assessment using the ASAS components indicated that the subjects had moderate mean values of disease activity and were well balanced between study arms. Approximately 92% of subjects had a history of NSAIDS usage, 13% had history of prior corticosteroid usage and 41% had received prior DMARDS. Approximately 32% of individuals in both arms were on protocol permissible DMARDS at baseline; the most common DMARD in both arms was Sulfasalazine (Table 4). Approximately 14% of placebo recipients and 12% of etanercept recipients received corticosteroids during the study, the most common reason for corticosteroid use was flare of pre-existent ocular inflammatory conditions.
Table 4 Baseline Disease Characteristics
|
Placebo |
Etanercept |
Characteristic
|
N = 139 |
N = 138 |
Mean duration of AS in years |
11 |
10 |
HLA B-27 |
109(84) |
108(84) |
Mean baseline ASAS components (range): |
|
|
Patient global assessment |
63(9–100) |
63(16–100) |
Nocturnal and total back pain |
62 (0–99) |
60 (6–100) |
BASFI |
56 (12–97.0) |
52 (4–98) |
Inflammation |
64 (7–100) |
61. (17–100) |
Concomitant therapy at baseline (n [%] |
|
|
Any DMARD |
43 (31) |
44 (32) |
Sulfasalazine (SSZ) |
30 (22) |
29 (21) |
Methotrexate (MTX) |
17 (12) |
15 (11) |
Hydroxychloroquine (HCL) |
1 (1) |
3 (2) |
Extra-Spinal
Inflammatory Signs/Symptoms
Overall approximately 30% of
participants had a history of or concurrent manifestations of extra-spinal
inflammatory signs and symptoms. occular
inflammation or uveitis/iritis
were the most common extra-spinal inflammatory conditions at approximately 30%
in both arms. Patients with history of inflammatory bowel disease and psoriasis
were included in the study and made up approximately 5% and 9% of the study
population respectively (Table 5). These factors were well
balanced between the two study arms.
Table 5 Extra-Spinal Inflammatory Symptoms
Extra-Spinal/Articular Inflammatory
Symptom |
Placebo n/N
% |
Etanercept n/N % |
Occular Inflammation |
39/139 (28) |
44/138 (32) |
Non-Infectious Conjunctivitis |
11/139
(8) |
9/138 (7) |
Uveitis or Iritis
|
43/139 (31) |
39/138 (28) |
Crohns Disease or Ulcerative Colitis |
6/139
(4) |
7/138 (5) |
Urethritis |
8/139
(6) |
5/138 (4) |
STD |
13/139 (9) |
11/138 (8) |
Psoriasis |
15/139 (11) |
11/138 (8) |
Table 6 Primary Endpoint Study 016.0037
Primary Endpoint |
|||
Number (%) Achieving ASAS 20 Response at
Week 12 |
|||
|
Placebo |
Etanercept |
|
Parameter |
N = 139 |
N = 138 |
P-value* |
ASAS 20 at 12 weeks |
38 (27) |
83 (60) |
< 0.0001 |
* P-value determined by Cochran-Mantel-Haenszel row means test. |
Table 7 Conditional Primary Endpoint Study 016.0037
Conditional Primary Endpoint: |
|||
Number (%) Achieving ASAS 20 at Week 24 |
|||
|
Placebo |
Etanercept |
|
Parameter |
N = 139 |
N = 138 |
P-value* |
ASAS 20 at 24 weeks |
32 (23) |
80 (58) |
< 0.0001 |
* P-value determined by
Cochran-Mantel-Haenszel row means test. |
Secondary Efficacy Analysis
There were 8 Secondary Efficacy Endpoints: Measurement of
ASAS 50/70 at 12 and 24 weeks, Highest ASAS level achieved at 12 and 24 weeks
and Frequency and time to Partial Remission as previously defined
ASAS 50/70 at 12 and 24 weeks
Higher levels of response using the ASAS Response Criteria
were analyzed. The superior performance of etanercept compared to placebo was
also seen in the ASAS 50 and 70 determinations with significant p-values at
both 12 and 24 weeks (Table 8).
Table 8 Secondary Endpoints ASAS 20, 50, 70: 12/24 weeks
Secondary Endpoints: |
|
||
|
Placebo |
Etanercept |
|
Parameter |
N = 139 |
N = 138 |
P-value*
|
ASAS 20 (n [%]) at: |
|
|
|
12 weeks |
38 (27) |
83 (60) |
< 0.0001 |
24 weeks |
32 (23) |
80 (58) |
< 0.0001 |
ASAS 50 (n [%]) at: |
|
|
|
12 weeks |
18 (13) |
62 (45) |
< 0.0001 |
24 weeks |
14 (10) |
58 (42) |
< 0.0001 |
ASAS 70 (n [%]) at: |
|
|
|
12 weeks |
10 (7) |
40 (29) |
< 0.0001 |
24 weeks |
7 (5) |
39 (28) |
< 0.0001 |
* P-value determined by Cochran-Mantel-Haenszel row means test. |
|
The onset of etanercept treatment effect compared to placebo began to be apparent as early as 2 weeks after treatment initiation. Maximal treatment effect was reached at approximately 8 weeks and sustained thereafter (see Figure 1). The time courses of effect with respect to ASAS 20, 50, and 70 values were similar although smaller proportions of patients attained the higher levels of response criteria (Figure 1)
Figure 1: Percent of Patients Achieving ASAS 20, ASAS 50, and ASAS 70 Over Time
Highest ASAS Responses at weeks 12/24
analysis of highest ASAS response achieved indicate
that among the patients whose highest response was ASAS 20 ( did not achieve an
ASAS 50 or ASAS 70 response), the numbers and percentages are similar between
the two study arms at the 12 and 24 week time points Higher proportions of etanercept
treated patients achieved higher level (ASAS 50, 70) responses (Table 9).
Table 9 Secondary Endpoint Study:
Highest ASAS Responses Achieved at weeks 12/24
|
Secondary Endpoint:
Highest ASAS 12/24 weeks |
|
||
|
|
Placebo |
Etanercept |
|
Time point |
Highest level of response |
N = 139 |
N = 138 |
P-value* |
Week 12 |
ASAS 20 non-responder |
101 (73) |
55 (40) |
< 0.0001 |
|
ASAS 20 responder |
20 (14) |
21 (15) |
|
|
ASAS 50 responder |
8 (6) |
22 (16) |
|
|
ASAS 70 responder |
10 (7) |
40 (29) |
|
Week 24 |
ASAS 20 non-responder |
107 (77) |
58 (42) |
< 0.0001 |
|
ASAS 20 responder |
18 (13) |
22 (16) |
|
|
ASAS 50 responder |
7 (5) |
19 (14) |
|
|
ASAS 70 responder |
7 (5) |
39 (28) |
|
* P-value determined by
Kolmogorov-Smirnov test. |
Partial
Remission
As previously indicated, partial remission was defined as achievement of a disease activity level <20 on VAS in all 4 ASAS domains. Etanercept patients achieved partial remission statistically more often than placebo both at the weeks 12/24 endpoints as well as any time during the study (Table 10).
Table 10 Secondary Endpoint Study Achievement of Partial
Remission
Secondary Endpoint:
Partial Remission |
|
||
|
Placebo |
Etanercept |
|
|
N = 139 |
N = 138 |
|
Time point |
n (%) |
n (%) |
P-value* |
Week 12 |
11 (8) |
29 (21) |
0.0020 |
Week 24 |
5 (4) |
24 (17) |
0.0002 |
Any time during the study |
15 (11) |
42 (30) |
< 0.0001 |
* P-value determined by
Cochran-Mantel-Haenszel row means test. |
|
The time to achievement of first
partial remission was also analyzed and etanercept was statistically superior
to placebo (log-rank p-value <0.0001) as shown graphically in (Figure 2).
Figure 2 Time to First Partial Remission
Other
Efficacy Analysis
Individual
Components of ASAS Response Criteria
Response data corresponding to
each of the components of the 4 domains that comprise the ASAS Response
Criteria were individually analyzed. The components analyzed using a Visual
Analog Scale were: patient global assessment, average of nocturnal back pain
and total back pain, the average of the 10 questions of the BASFI (function)
and the last two questions of the BASDAI (inflammation). The results of this
analysis indicated that subjects receiving etanercept had statistically greater improvement in each
of the ASAS components than did subjects receiving placebo (Table 11).
Table 11 ASAS Individual Components
ASAS Individual Components |
|||||
Mean (median) Values and Percent Improvement from Baseline |
|||||
|
|
Mean(median) |
|||
|
Mean (median) Values |
Percent Improvement from Baseline |
|||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Parameter
|
N = 139 |
N = 138 |
N = 139 |
N = 138 |
|
Patient’s Global Assessment
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
Baseline |
63 (64) |
63 (66) |
|
|
|
12 weeks |
56 (57) |
35 (32) |
10 (9) |
40.2 (51) |
< 0.0001 |
24 weeks |
56 (57) |
36 (29) |
8 (7) |
38.6 (46) |
< 0.0001 |
Average of Nocturnal Back Pain/ Total
Back Pain |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline
|
62 (65) |
60 (62) |
|
|
|
12 weeks |
55 (56) |
33 (26) |
7 (5) |
40 (54) |
< 0.0001 |
24 weeks |
56 (61) |
34 (26) |
5 (6) |
35 (51) |
< 0.0001 |
BASFI |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline
|
56 (59) |
52 (50) |
|
|
|
12 weeks |
53 (53) |
35 (29) |
5 (3) |
33 (32) |
< 0.0001 |
24 weeks |
55 (55) |
36 (31) |
2 (1) |
30 (31) |
< 0.0001 |
BASDAI (last 2 questions) |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline
|
64 (65) |
61.4 (60) |
|
|
|
12 weeks |
53 (49) |
32.8 (21) |
13 (10) |
45 (55) |
< 0.0001 |
24 weeks |
57 (58) |
33.4 (26) |
6 (5) |
44 (45) |
< 0.0001 |
Additional
Outcome Measurements
Efficacy measurements not part of the ASAS Response Criteria but which had been used in other studies of Ankylosing Spondylitis were also analyzed. These outcome measurements included: BASDAI (all 6 questions), spinal mobility parameters, peripheral tender and swollen joints, acute phase reactants and assessor global assessment.
BASDAI
The last 2 questions of the
BASDAI deal with inflammation and are assessed in the ASAS response criteria.
The other 4 questions address fatigue; AS related neck, back or hip pain;
non-AS pain and swelling of joints and tenderness to touch of any areas. These
data were collected and the results are presented in (Table 12). Again, the improvement in the etanercept group is
statistically superior to the placebo.
Table 12 BASDAI Average of 6 questions
|
|
|
Mean (median) |
||
|
Mean (median) Values |
Percent Improvement from Baseline |
|||
BASDAI – average of |
Placebo |
Etanercept |
Placebo |
Etanercept |
|
responses to 6 questions |
N = 139 |
N = 138 |
N = 139 |
N = 138 |
P-value* |
Baseline |
60 (60) |
58 (57) |
|
|
|
12 weeks |
52 (50) |
33(27) |
11 (10) |
42 (45) |
< 0.0001 |
24 weeks |
55 (58) |
35 (33) |
6 (3) |
40 (40) |
< 0.0001 |
* P-value determined by Cochran-Mantel-Haenszel row means test with
Modridit option on percent |
|||||
improvement from baseline. |
Spinal
Mobility Parameters
Spinal mobility was judged by the ASAS Working Group as the fifth important domain in the assessment of clinically important short-term therapeutic response in Ankylosing Spondylitis but this domain was not included in the ASAS Response Criteria (see Development of Efficacy Endpoints for Clinical Trials pg 3). Assessment of Spinal Mobility was separately performed in this study and these data are presented in (Table 13). Statistically significant improvements in spinal mobility in all three measured parameters were demonstrated by etanercept. The parameter demonstrating the greatest improvement was Occiput to wall measurement.
Table 13 Other Endpoints: Spinal Mobility Parameters
Spinal Mobility Parameters: |
|||||
Mean (median) Values and Percent Improvement from Baseline |
|||||
|
|
Mean (median) |
|||
|
Mean (median) Values (cm) |
Percent Improvement from Baseline* |
|||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
Parameter |
N = 139 |
N = 138 |
N = 139 |
N = 138 |
P-value† |
Modified Schober’s test |
|
|
|
|
|
Baseline
|
3.0 (3) |
3.1 (3) |
|
|
|
12 weeks |
3.1 (3) |
3.3 (3) |
21 (0) |
26 (9) |
0.0359 |
24 weeks |
2.9 (3) |
3.3 (4) |
8 (0) |
25 (10) |
0.0014 |
Chest expansion |
|
|
|
|
|
Baseline
|
3.2 (3) |
3.3 (3) |
|
|
|
12 weeks |
3.2 (3) |
3.8 (3) |
11 (0) |
58 (5) |
0.0026 |
24 weeks |
3.0 (3) |
3.9(4) |
-<1 (0) |
57 (17) |
< 0.0001 |
Occiput-to-wall Measurement |
|
|
|
|
|
Baseline
|
5.3 (3) |
5.6 (5) |
|
|
|
12 weeks |
5.7 (3) |
4.9 (3) |
-18 (0) |
18 (16) |
0.0034 |
24 weeks |
6.0 (3) |
4.5(1) |
-18 (0) |
26 (25) |
< 0.0001 |
* Patients with a score of zero at baseline were not included in the analysis of percent improvement from baseline. |
|||||
The number of patients
with a zero baseline score varied, depending on the parameter of interest. |
|||||
† P-value determined by
Cochran-Mantel-Haenszel row means test with Modridit option on percent |
|||||
improvement from baseline. |
|
|
|
|
Peripheral Tender and Swollen Joint Counts
Improvement in peripheral joint symptoms have been analyzed in other studies of Ankylosing Spondylitis and were assessed here. Treatment with etanercept was associated with statistically significant improvement in numbers of tender peripheral joints (Table 14). There was, however, no corresponding statistically significant improvement in the numbers of swollen joints (Table 14). The explanation for this finding is not established but is possibly related to the small number of involved joints symptoms in subjects in both study arms or to the lack of etanercept efficacy. At baseline, 82% of placebo recipients and 73% of etanercept recipients had at least one tender peripheral joint, 47% and 53% of these same groups had evidence of swelling in at least one peripheral joint. For those individuals who did have tender joints at baseline, the mean number was 9 in placebo and 7 in etanercept arms, with corresponding medians of 4 and 3 respectively. The mean number of swollen joints was 4 in both arms with corresponding medians of 0 for placebo and 1 for etanercept.
Table 14 Other Endpoints: Peripheral Tender and Swollen
Joint Counts
Peripheral Tender and Swollen Joint Counts |
|||||
Mean (median) Values and Percent
Improvement from Baseline |
|||||
|
|
Mean (median) |
|
||
|
Mean (median) Values |
Percent Improvement from Baseline* |
|||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
Parameter
|
N = 139 |
N = 138 |
N = 139 |
N = 138 |
P-value† |
Tender joints |
|
|
|
|
|
Baseline |
9 (4) |
7 (3) |
|
|
|
12 weeks |
8 (2) |
5 (1) |
-1.0 (21) |
37 (50) |
0.0061 |
24 weeks |
8 (2) |
5 (1) |
1.4 (31) |
36 (62) |
0.0014 |
Swollen joints |
|
|
|
|
|
Baseline |
4 (0) |
4 (1) |
|
|
|
12 weeks |
4 (0) |
3 (0) |
-15 (50) |
36 (66) |
0.1263 |
24 weeks |
3 (0) |
2 (0) |
-11 (50) |
4 (60) |
0.8384 |
* Patients with a count of
zero at baseline were not included in the analysis of percent improvement
from |
|||||
baseline. The number of
patients with a zero baseline score varied, depending on the parameter of
interest. |
|||||
† P-value determined by
Cochran-Mantel-Haenszel row means test with Modridit option on percent |
|||||
improvement from baseline. |
|
|
|
|
|
Acute
Phase Reactants
At baseline the acute phase reactants, ESR and CRP were within the normal range in approximately 53% of placebo recipients and 46% of etanercept recipients. The changes in these acute phase reactants during the study demonstrate statistical significant improvement in both at the 12 and 24 week time point (Table 15). This improvement is also seen in the number of subjects whose values enter the normal range. At 24 weeks of treatment, the number of placebo recipients with ESR and CRP in the normal range was unchanged but the number among the etanercept recipients had increased to approximately 84%.
Table 15 Other Endpoints: Acute Phase Reactants
Acute Phase Reactants |
||||||
Mean (median) Values and
Percent Improvement from Baseline
|
||||||
|
|
Mean (median) |
|
|||
|
Mean (median) Values |
Percent Improvement from Baseline* |
||||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
|
Parameter
|
N = 139 |
N = 138 |
N = 139 |
N = 138 |
P-value† |
|
ESR (mm/hr)‡ |
|
|
|
|
|
|
Baseline |
25 (17) |
26 (23) |
|
|
|
|
12 weeks |
26 (16) |
13 (9) |
-19 (0) |
18 (60) |
< 0.0001 |
|
24 weeks |
26 (19) |
11 (7) |
-23 (0) |
42 (60) |
< 0.0001 |
|
CRP (mg/dL)** |
|
|
|
|
|
|
Baseline |
2 (1) |
2 (1) |
|
|
|
|
12 weeks |
2 (1) |
1 (0.2) |
-143 (-5.4) |
10 (69) |
< 0.0001 |
|
24 weeks |
2 (1) |
<1 (0.3) |
-96 (0) |
38 (73) |
< 0.0001 |
|
‡
Erythrocyte sedimentation rate (ESR) normal range: 1–17 mm/hr for men; 1–25
mm/hr for women.
**C-reactive protein (CRP) normal range: 0–1.0 mg/dL.
Assessor Global Assessments
In the same manner as Physician Global Assessments have been
used to complement Patient Global Assessments for therapeutic measurements in
other rheumatologic disorders, they have been studied in Ankylosing Spondylitis
and were analyzed in this study. As
demonstrated in (Table 16), the
Assessor Global Assessment showed statistically significant improvement among
the etanercept recipients at both the 12 and the 24 week time points.
Table 16 Other Endpoints: Assessor Global Assessments
Assessor Global Assessments |
||||||
Mean (median) Values and Percent Improvement from Baseline |
||||||
|
|
Mean (median) |
|
|||
|
Mean (median) Values |
Percent Improvement from Baseline |
||||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
|
Parameter
|
N = 139 |
N = 138 |
N = 139 |
N = 138 |
P-value* |
|
Assessor’s Global
Assessment
|
|
|
|
|
|
|
Baseline
|
57 (58) |
54 (57) |
|
|
|
|
12 weeks |
48 (50) |
33
(30) |
10 (14) |
34 (45) |
< 0.0001 |
|
24 weeks |
49 (51) |
34 (30) |
6 (13) |
30 (45) |
< 0.0001 |
|
* P-value determined by
Cochran-Mantel-Haenszel row means test with Modridit option on percent
improvement from baseline. |
||||||
Table 17 Exploratory Analysis: Number(%) Achieving ASAS
DCART 20 and ASAS DCART 40
Exploratory Analysis: ASAS DCART 20/40 |
|||
Number (%) Achieving ASAS DCART 20 /40
Responses |
|||
|
Placebo |
Etanercept |
|
DCART-proposed Parameter |
N = 139 |
N = 138 |
P-value* |
ASAS DCART 20 (n [%]) at: |
|
|
|
2 weeks |
7 (5) |
41 (30) |
< 0.0001 |
12 weeks |
11 (8) |
51 (37) |
< 0.0001 |
24 weeks |
10 (7) |
46 (33) |
< 0.0001 |
ASAS DCART 40 (n [%]) at: |
|
|
|
2 weeks |
11 (8) |
38 (28) |
< 0.0001 |
12 weeks |
21 (15) |
59 (43) |
< 0.0001 |
24 weeks |
18 (13) |
57 (41) |
< 0.0001 |
* P-value determined by Cochran-Mantel-Haenszel row means test. |
|
Measurement of ASAS 20 at both 12 and 24 week permits exploration of response dynamics to include treatment response duration and delay. As presented in (Table 18) 86% of subjects receiving etanercept who had achieved an ASAS 20 at week12 also had an ASAS 20 response at 24 weeks compared to 66% of placebo. Further, the treatment difference between etanercept and placebo12 week responders continues unchanged at 24 weeks. The percentage of etanercept recipients who lost ASAS 20 response in the 12 weeks between measurements was less than half of that of placebo recipients and the percentage achieving ASAS 20 for the first time was twice as high (15% versus 7%). This suggests that most patients who achieve an ASAS 20 response on etanercept will achieve that response by 3 months.
Table 18 Duration of ASAS 20 and Delay in Attainment of ASAS
20
Exploratory Analysis: Duration of ASAS 20
and Delay in attainment |
||
|
Placebo |
Etanercept |
Parameter |
N = 139 |
N = 138 |
ASAS 20 or higher (n [%]) at: |
|
|
12 weeks |
38 (27) |
83 (60) |
24 weeks |
32 (23) |
80 (58) |
ASAS 20 at 12 wks also responders at
24wks |
25/38 (66) |
71/83 (86) |
ASAS 20 at both 12/24 wks/ITT population |
25/139 (18) |
71/138 (51) |
Positive to Negative |
13/38 (34) |
12/83 (14) |
Negative to Positive |
7/101 (7) |
8/55 (15) |
Exploratory
Analysis: Impact of Gender, Race and
Site on ASAS 20
76% of study participants were male and the treatment difference between etanercept and placebo for men is 38% Etanercept also appears to be beneficial for women but the treatment associated difference appears blunted at 17% (Table 19).
The significance of this finding is unknown and
may be due to wider confidence intervals
due to the small number of females enrolled. The impact of race upon the ASAS
20 is difficult to assess since only 20
non-caucasians were enrolled. Geographic site did not appear to have a
significant impact upon the ASAS 20 treatment response (Table 19).
Table 19 Exploratory Analysis: ASAS 20 at 12wks by baseline
non-disease associated factor
Exploratory Analysis: ASAS 20 Non-disease
Associated factor |
|||
Baseline Characteristic |
Status |
Placebo n/N (%) |
Etanercept n/N (%) |
Sex |
Male |
28/105 (27) |
68/105 (65) |
|
Female |
10/34 (29) |
15/33 (45) |
Race |
Caucasian |
36/127 (28) |
76/130 (58) |
|
Non-Caucasian |
2/12 (17) |
7/8 (88) |
Site |
North American |
34/109 (31) |
63/106 (59) |
|
European |
4/30 (13) |
20/32 (63) |
Table 20 Exploratory Analysis: ASAS 20 at 12wk by Age,
Weight and Duration of Disease
Characteristic |
Placebo N/N (%) |
Etanercept N/N (%) |
Whole
Population |
38/139 (27) |
83/138 (60) |
AGE |
|
|
<34 |
12/38 (32) |
23/31 (74) |
34 to <42 |
6/25 (24) |
24/37 (65) |
42 to <50 |
10/35 (29) |
23/41 (56) |
50+ |
10/41 (24) |
13/29(45) |
WEIGHT |
|
|
<68kg |
9/33 (27) |
16/29 (55) |
68 to <80kg |
9/26 (35) |
28/45 (62) |
80 to <93kg |
10/40 (25) |
18/32 (56) |
93+ kg |
10/39 (26) |
20/31 (65) |
Disease Duration |
|
|
<2.25yrs |
16/35 (46) |
20/34 (59) |
2.25 to
<8.75yrs |
8/35 (23) |
19/34 (56) |
8.75 to
<16.25yrs |
4/31 (13) |
25/38 (66) |
16.25+ yrs |
10/38 (26) |
19/32 (59) |
Exploratory
Analysis: Impact of Concomitant Non-Skeletal Inflammatory Disorders upon ASAS
20 at 12 weeks.
Patients
with non-skeletal inflammatory disorders associated with Ankylosing Spondylitis
such as uveitis as well as conditions associated with other
spondyloarthropathies such as psoriasis were enrolled in this study. The impact
of these conditions upon ASAS 20 response was explored. History of
Uveitis/Iritis, inflammatory bowel disease and risk of reactive arthritis did
not appear to have any adverse impact upon the ASAS 20 response to etanercept (Table
21).
Table 21 Exploratory Analysis: ASAS 20 at 12 wks in subjects with
Concomitant Non-Skeletal Inflammatory Disorders
Baseline Characteristic |
Status |
Placebo n/N (%) |
Etanercept n/N (%) |
Hx Uveitis or Iritis |
No |
26/96 (27) |
58/99(59) |
|
Yes |
12/43 (28) |
25/39 (64) |
Hx Psoriasis |
No |
33/124 (27) |
78/127 (61) |
|
Yes |
5/15(33) |
5/11(45) |
Hx IBD |
No |
38/133(29) |
78/131(60) |
|
Yes |
0/6(0) |
5/7(71) |
Hx bacterial dysentery, urethritis Chlamydia, STD |
No |
33/126 (26) |
76/127(60) |
|
Yes |
5/13 (38) |
7/11(64) |
Exploratory Analysis: Impact of prior and or concomitant medications upon ASAS 20 at 12 weeks.
The majority of subjects had history of either prior or concomitant medications. Approximately 31% were receiving concomitant DMARDS and the study was stratified to consider DMARD use. Exploratory analysis of the impact of prior or concomitant medication use did not indicate a significant effect on the ASAS 20 at 12 weeks
(Table 22). Subjects using NSAIDS appeared to have higher response to etanercept than those without such use but the numbers are small. Of the DMARDS, responses to etanercept were higher among patients receiving concomitant Sulfasalazine compared to other DMARDS. Methotrexate use, however, appeared to be associated with a lower response but again the numbers are small and no definite conclusions can be reached.
Table 22 Exploratory Analysis: ASAS 20 at 12 weeks compared with prior/concomitant medications
Baseline
Characteristic |
Status |
Placebo N/N (%) |
Etanercept N/N (%) |
NSAIDS w/i 6mo
Screening |
No |
3/11 (27) |
6/12(50) |
|
Yes |
35/128 (27) |
77/126 (61) |
Corticosteroids
w/i 6mo Scr |
No |
37/119 (31) |
72/120(60) |
|
Yes |
1/20 (5) |
11/18(61) |
Concomitant
DMARD(s) |
No |
29/96 (30) |
56/94(60) |
|
Yes |
9/43 (21) |
27/44(61) |
Concomitant
sulfasalazine |
No |
31/109 (28) |
63/109 (58) |
|
Yes |
7/30 (23) |
20/29 (69) |
Concomitant
methotrexate |
No |
35/122 (29) |
75/123(61) |
|
Yes |
3/17 (18) |
8/15 (53) |
Exploratory Analysis:
Impact of Baseline Disease Severity upon the ASAS 20 at 12 weeks
The impact of baseline disease severity upon the
response to etanercept was explored using individual components of the ASAS
response criteria and hip involvement, a prognostic factor in ankylosing
spondylitis. The superiority of etanercept was preserved for each individual
component for both high and low baseline disease severity. There were, however,
differences in the magnitude of response and in the treatment difference
compared to placebo. For the components of average back pain, patient global
assessment, and the last two questions of the BASDAI (inflammation) those
demonstrating greater disease severity at baseline had higher percentages of
ASAS 20 achievement and wider treatment differences compared to placebo (Table 23). For the BASFI, although the treatment difference is
higher in the population with greater disease severity, the percentage
achieving ASAS 20 was lower (Table 23). A possible explanation for these differences
may be that the disease severity measured in the first three components has a
stronger relationship to inflammation than does the functionality measured in
the BASFI. The presence of hip
involvement did not appear to have a significant impact upon the ASAS 20
achievement percentages.
Table 23 Exploratory Analysis:
ASAS 20 at 12 wks compared with baseline individual disease severity
Baseline
Characteristic |
Status |
Placebo |
Etanercept |
Average Back
Pain-total |
£
Median =63 |
22/65 (34) |
40/74 (54) |
|
> Median=63 |
16/74 (22) |
43/64 (67) |
Patient Global
Assessment |
£
Median=65 |
22/74 (30) |
39/68 (57) |
|
> Median=65 |
16/65 (25) |
44/70 (63) |
BASFI |
£
Median=53.4 |
22/61 (36) |
50/78 (64) |
|
>
Median=53.4 |
16/78 (21) |
33/60 (55) |
Average last 2
BASDAI |
£
Median=62.5 |
19/65 (29) |
43/74 (58) |
|
>
Median=62.5 |
19/74 (26) |
40/64 (63) |
Hip disease or
limited ROM of Hip |
No |
9/31 (29) |
27/44 (61) |
|
Yes |
29/107 (27) |
50/85 (59) |
Further exploration of the
relationship between baseline disease severity and the percentage of ASAS
response was performed to include further refinement of severity measurement as
well as treatment duration. As shown in (Table 24), at 12
weeks, subjects with baseline back pain measured <50 had the lowest ASAS 20
and treatment difference compared with placebo. ASAS 20 and treatment
difference percentages do not increase in a strictly linear manner, however. The highest ASAS 20 and treatment difference
percentage were actually found in those with a baseline back pain VAS of
between 63 and 76 (Table
24). These findings persist at 24 weeks (Table 24).
Table 24 Exploratory Analysis: ASAS 20 at 12/24wks by
Baseline Back Pain
Baseline Back pain |
Placebo N/N (%) |
Etanercept N/N (%) |
Week 12 |
|
|
All |
38/134 (28) |
83/133 (62) |
<50 |
9/26 (35) |
19/37 (51) |
50 to <63 |
13/36 (36) |
20/32 (63) |
63 to <76 |
9/36 (25) |
24/33 (73) |
76+ |
7/36 (19) |
20/31(65) |
Week 24 |
|
|
All |
32/121 (26) |
80/125 (64) |
<50 |
10/24 (42) |
19/33 (58) |
50 to <63 |
11/32 (34) |
18/29 (62) |
63 to <76 |
7/34 (21) |
24/32 (75) |
76+ |
4/31 (13) |
19/31 (61) |
84% of the study population was positive for HLA B27 antigen. Examination of the impact of the presence or absence of this antigen on the ASAS 20/50/70 response rates at 12 and 24 weeks indicate that for the ASAS 20 and ASAS 50 measurements, subjects that were HLA-B27 antigen positive had a better response to etanercept than the entire population (Table 25). Conversely, although consistently higher than placebo in all comparisons, etanercept recipients who were HLA-B27 antigen negative had lower ASAS 20 and 50 response percentages at 12 weeks and 24 weeks compared to those of the HLA-B27 positive patients (Table 25). The ASAS 70 determinations in etanercept recipients appeared to be approximately the same in the two subpopulations at both times. The explanation for this apparent blunting of the ASAS 20/50 response at 12 and 24 weeks is unknown but it should be kept in mind that only small numbers of HLA-B27 antigen negative patients were enrolled.
Table 25 Exploratory Analysis: ASAS 20/50/70: HLA B27 Known
Secondary Endpoints: Impact HLA-B27 |
||||
|
HLA B27 Positive |
HLA B27 Negative |
||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
Parameter |
N = 109 |
N = 108 |
N = 19 |
N = 21 |
ASAS 20 (n [%]) at: |
|
|
|
|
12 weeks |
31 (28) |
70 (65) |
5 (26) |
8 (38) |
24 weeks |
26
(24) |
67 (62) |
3
(16) |
9 (43) |
ASAS 50 (n [%]) at: |
|
|
|
|
12 weeks |
14 (13) |
53 (49) |
3 (16) |
6 (29) |
24 weeks |
11 (10) |
49 (45) |
2 (11) |
7 (33) |
ASAS 70 (n [%]) at: |
|
|
|
|
12 weeks |
7 (6) |
33 (31) |
2
(11) |
6 (29) |
24 weeks |
5
(5) |
31 (29) |
2
(11) |
6 (29) |
Safety Analyses
Overview of Adverse Events
Table 26 Adverse Events in ³ 5% of Patients
Adverse Events of All Intensities in ³5%
of Patients in Either Treatment Group |
||
|
Proportions of Patients (n [%]) |
|
|
Placebo |
Etanercept |
Event |
N = 139 |
N = 138 |
Any adverse event |
105 (76) |
99 (72) |
Infections |
42 (30) |
57 (41) |
Injection site reaction |
13 (9) |
41 (30) |
Injection site ecchymosis |
23 (17) |
29 (21) |
Headache |
16 (12) |
19 (14) |
Accidental injury |
6 (4) |
17 (12) |
Diarrhea |
13 (9) |
11 (8) |
Rash |
9 (7) |
11 (8) |
Dizziness |
3 (2) |
8 (6) |
Rhinitis |
9 (7) |
8 (6) |
Abdominal pain |
7 (5) |
8 (6) |
Nausea |
7 (5) |
7 (5) |
Asthenia |
7 (5) |
5 (4) |
The incidence of severe and serious adverse events as well
as discontinuations for adverse events were numerically higher in the
etanercept arm compared to the placebo arm (Table
27). There were no discontinuations for laboratory abnormalities.
Table 27 Tabulation of Important Safety Outcomes
Safety Outcomes
|
Placebo N=139 n/N % |
Etanercept N=138 n/N % |
Serious Adverse Events
|
5 (4) |
9 (7) |
Withdrawals
for Safety |
1(1) |
7 (5) |
Grade 3/4
Adverse Events/ Infections |
4(3) |
14 (10) |
Grade 3/ 4
Abnormal Laboratory |
0 (0) |
2*(1) |
* 1 Grade 3 Low
ANC, 1 Grade 3 Low Lymphocytes
Serious
Adverse Events
10 SAE occurred in 9 etanercept recipients and 5 SAE occurred in 5 placebo patients (Table 28). Infections and accidental injury occurred in both study arms but were more frequently encountered among the etanercept patients. Serious infections will be discussed separately. Of the remaining Serious Adverse Events in the etanercept group, one patient developed a febrile reaction with rash suggestive of a hypersensitivity reaction, another developed transient unilateral lymphadenopathy (with equivocal PPD positivity) that resolved without treatment and another patient with a past history of ulcerative colitis developed pancolitis while on treatment that necessitated study discontinuation.
Table 28 Serious Adverse Events
Patient no. |
Sex/Age |
D/C Date |
Cause |
Grade |
Comments |
Placebo |
|
|
|
|
|
163 |
M/45 |
25 |
Industrial
Accident |
3 |
Hospitalized |
245 |
M/29 |
164 |
Viral
Infection |
2 |
Hospitalized |
268 |
M/49 |
141 |
Suicide Attempt |
4 |
Hx Major
Psychiatric Dz |
562 |
M/50 |
15 |
MVA back
injury |
3 |
D/C LOE |
572 |
F/48 |
100 |
Chest Pain |
2 |
Hospitalized
w/ recur CP r/oMI |
Etanercept |
|
|
|
|
|
158 |
M/53 |
23 |
Febrile
Reaction |
3 |
3hr p w/rash |
167 |
M/60 |
141 |
Lymphadenopathy |
2 |
+/- PPD -INH
prophylaxis |
191 |
M/28 |
94 |
Cellulitis
insect bite |
3 |
Hospitalization |
241 |
M/43 |
129 |
Vertebral Fx
MVA |
3 |
Hospitalization |
269 |
M/64 |
71 |
Fibular
fracture fall |
3 |
Multiple
Med-problems |
513 |
M/34 |
82 |
Cellulitis cat
bite |
3 |
Hospitalized |
515 |
F/49 |
43 |
Fx Elbow fall |
3 |
Hospitalized |
559 |
M/44 |
110 |
Pancolitis UC |
3 |
Hx IBD switch
TNF |
580 |
M/56 |
144 |
Intestinal
Obstruction |
3 |
Prior Surgery Adhesions |
As previously shown in (Table 28), there were 3 infections that were considered serious, one in the placebo arm and the other two in the etanercept arm. In both instances in the etanercept arm, the serious infections both involved cellulitis associated with an antecedent injury; one an insect bite, the other a cat bite, and both required intravenous antibiotics to control the infection. Staphlococcus aureus was recovered in the insect bite cellulitis, the presumed bacterial cause of the cat bite related cellulitis was not recovered.
Infections of all intensities
were more common in etanercept recipients. The predominant cause appears to be
the greater incidence of upper respiratory tract infections (Table 29).
Table 29 Infections of All Intensities in ³ 5% of Patients
Infections of All Intensities in ³ 5% of Patients in Either Treatment Group |
||
|
Proportions of Patients (n [%]) |
|
|
Placebo |
Etanercept |
Event |
N = 139 |
N = 138 |
Any infection |
42 (30) |
57 (41) |
Any infection except URI |
28 (20) |
33 (24) |
Upper respiratory infection |
16 (12) |
28 (20) |
Flu syndrome |
10 (7) |
5 (4) |
If patients treated with oral or parenteral systemic antimicrobials are compared between etanercept and placebo, the important contribution of bacterial causes to the increased incidence of URI becomes apparent (Table 30). Dental infections and sinusitis in particular appeared to be numerically more prevalent among etanercept recipients than in placebo recipients.
Cellulitis requiring antibiotics was also more prevalent in the etanercept group but the numbers were small, the higher incidence of intravenous antibiotics in the etanercept group was largely caused by 3 SAE: the two serious infections (previously mentioned) and the patient with exacerbation of ulcerative colitis (Table 30).
Table 30 Infections Requiring Oral or Parenteral Systemic
Antimicrobials
Infections Requiring Oral or Parenteral
Systemic Antimicrobial Therapy (AMT) |
Placebo n/N
% |
Etanercept n/N % |
Total number of subjects receiving AMT/
Total Study Population |
21/139 (15) |
27/138 (20) |
URI/Dental/Sinusitis/Otitis Media |
9/21 (43) |
14/27 (52) |
Bronchitis/Pneumonia |
3/21 (14) |
3/27 (11) |
UTI or GYN |
3/21 (14) |
3/27 (11) |
Cellulitis |
1/21 (5) |
3/27 (11) |
GI/Colitis |
1/21 (5) |
2/27 (7) |
Antibiotic Prophylaxis |
4/21 (19) |
4/27 (15) |
IV Antibiotics |
0/21 (0) |
3/27 (11) |
Study Withdrawals
for Safety
There
was one withdrawal from study for safety in the placebo arm compared to seven
withdrawals in the etanercept arm (Table 31). There is overlap
between safety withdrawals and patients with SAE since some of these were
discontinued. Of the seven withdrawals in etanercept recipients, 4 were for
bowel related. One of these was a bowel obstruction secondary to surgical
adhesions, the other three were for symptoms suggestive of inflammatory bowel
disease (IBD). One episode occurred in an individual with medical history
suggestive of IBD prior to enrollment, the other two did not give a history of
IBD prior to enrollment but upon questioning, had histories that were
suggestive of IBD. Two of the three episodes were diagnosed as inflammatory
bowel disease, one was a recurrence in the previously diagnosed patient, and
the other was a new diagnosis. The third patient was evaluated and colonoscopic
evaluation did not reveal IBD; his diarrhea was attributed to study drug with
hemorrhoidal bleeding. Of the 6 individuals with history of IBD prior to
enrollment in the placebo arm, none were withdrawn for flare of IBD. Of the 7
individuals in the etanercept arm with a history consistent with IBD prior to
enrollment, 3 developed bloody diarrhea of sufficient severity to withdraw from
study, two diagnosed as having a flare of IBD.
Table 31 Study Withdrawals for Safety
Patient no. |
Sex/Age |
D/C Date |
Cause |
Grade |
Comments |
Placebo |
|
|
|
|
|
268 |
M/49 |
141 |
Suicide
Attempt |
4 |
Hx Major
Psychiatric Dz |
Etanercept |
|
|
|
|
|
123 |
M/30 |
29 |
LGI Bleed
Hemorr Negative IBD |
2 |
Hx c/w IBD |
158 |
M/53 |
23 |
Febrile
Reaction |
3 |
3hr p w/rash |
241 |
M/43 |
129 |
Vertebral Fx
MVA |
3 |
Surgical
Intervention |
253 |
M/54 |
54 |
Ileitis from
Crohns |
1 |
Hx IBD switch
TNF |
269 |
M/64 |
71 |
Fibular
fracture fall |
3 |
Multiple
Med-problems |
559 |
M/44 |
110 |
Pancolitis UC |
3 |
Hx IBD switch
TNF |
580 |
M/56 |
144 |
Intestinal
Obstruction |
3 |
Prior Surgery Adhesions |
Grade
3 and 4 Adverse Events not considered to be SAE
6 patients, one in the placebo
arm and the other 5 in the etanercept arm developed Grade 3 Adverse Events
(there were no grade 4) (Table 32). Two in the etanercept arm and
one in the placebo experienced elevated blood pressure, one in each arm due to
changes in pre-study anti-hypertensives, the remaining etanercept patient
developed hypertension for the first time which was easily medically
managed. The two remaining etanercept
patients developed severe neurologic adverse events; one a 12 day migraine
headache (prior history of migraines) and the other a grand mal seizure which
was ultimately attributed to a abrupt withdrawal from chronic lorazepam and
oxycodone administration. seizures
are mentioned in the current package insert under
Warnings, neurologic.
Table 32 Grade 3/4
Adverse Events/Infections Not SAE
Patient no. |
Sex/Age |
D/C Date |
Cause |
Grade |
Comments |
Placebo |
|
|
|
|
|
119 |
F/52 |
|
hypertension |
3 |
Change in
Hypertension Rx |
Etanercept |
|
|
|
|
|
126 |
F/30 |
35 |
Migraine
x12days |
3 |
Completed
Study |
238 |
M/32 |
59 |
Gran Mal SZ |
3 |
Abrupt d/c
Valium |
253 |
M/54 |
94 |
Hypertension |
3 |
Change in
Hypertension Rx |
505 |
F/50 |
16 |
Asthma/Dehydration |
3 |
Hx Asthma
required ER visit |
523 |
F/42 |
42 |
Hypertension |
3 |
New
Hypertension |
Many of the patients enrolled in
both arms of this study had Grade 1 and 2 laboratory abnormalities at baseline.
Absolute neutrophil counts (ANC) were elevated in 27%, lymphocytes were low in
26%, hemoglobin was low in 18%, platelets were high in 32%, liver associated
enzymes were elevated in 5-9%, urine proteinuria was present in 2-5% (Table 33). During the study, these values remained stable in
the placebo recipients but some did change in the etanercept recipients. High ANC decreased by 10%, low Lymphocytes
decreased by 12%, low hemoglobin decreased by 10%, and high platelet counts
decreased by 19% (Table
33). All of these changes are compatible with the
anti-inflammatory activity of etanercept on acute phase reactants. Liver
associated enzymes were essentially unchanged. Etanercept antibodies were
detected in 2.2% of etanercept recipients. None of these anti-etanercept
antibodies were neutralizing.
Table 33 Laboratory Abnormalities Prior and During Study
|
Placebo |
Etanercept 25mg BIW |
||
Laboratory Values
|
Baseline n/N % |
During Study n/N % |
Baseline n/N % |
During Study n/N % |
ANC High |
38/138 28 |
31/138 23 |
37/138 27 |
23/136 17 |
ANC Low |
2/138 1 |
2/138 1 |
1/138 1 |
5/136 4 |
Lymphocytes
Low |
32/138 23 |
36/138 26 |
40/138 29 |
23/136 17 |
Hemoglobin Low |
25/138 18 |
31/138 23 |
26/138 19 |
12/136 9 |
Platelets High |
48/138 35 |
43/138 31 |
40/138 29 |
13/136 10 |
Platelets Low |
0/138 0 |
0/138 0 |
0/138 0 |
3/136 2 |
SGOT High |
7/138 5 |
7/138 5 |
5/138 4 |
10/135 7 |
SGPT High |
13/139 9 |
10/138 7 |
13/138 9 |
15/135 11 |
Urine
Proteinuria |
3/138 2 |
6/135 4 |
7/138 5 |
5/136 4 |
Etanercept
Antibodies |
N/A |
N/A |
0/136 0 |
3/136 2.2 |
Efficacy
In study 016.0037, etanercept 25mg sc biw was superior to placebo in the achievement of ASAS 20 Response Criteria response at 12 and 24 weeks in patients with active Ankylosing Spondylitis. The treatment difference is an absolute 33%, which is statistically significant at a level of p <0.0001. The treatment difference is retained at 24 weeks. favorable treatment differences with etanercept at higher levels of ASAS Response were also statistically significant at both 12 and 24 weeks.
Responses for all four domains of the ASAS Response Criteria also supported the superiority of etanercept. The fifth domain recommended by the ASAS Working Group, Spinal mobility was measured and found to be statistically superior to placebo. Etanercept recipients experienced statistically significant improvement in numbers of tender peripheral joints but not in improvement in numbers of swollen joints. Acute phase reactants ESR and CRP were statistically improved in etanercept recipients compared to placebo recipients.
Exploratory analyses indicated that other proposed Ankylosing Spondylitis Clinical Response Criteria such as DCART 20 and DCART 40 also supported etanercept’s superiority over placebo at 12 and 24 weeks.
All subgroup analyses performed indicated that etanercept was superior to placebo although increasing age, female gender, being HLA-B27 negative, having concomitant psoriasis all appeared to be associated with some blunting of the benefit. The use of DMARDS did not appear to affect the treatment difference.
“MULTICENTRE,
DOUBLE-BLIND, PARALLEL ARM, PLACEBO-CONTROLLED,RANDOMISED PHASE 3 STUDY OF
ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS”
Study 47687 was a randomized, multi-center, international, double blinded, placebo controlled phase 3 study of etanercept versus placebo in 84 patients with active ankylosing spondylitis. Subjects were randomly assigned to one of two treatment arms: etanercept 25mg sc biw or placebo on a 1:1 basis. Subjects were treated for a total of 12 weeks with the primary endpoint of achievement of ASAS 20 response criteria. There were 15 days of safety follow-up. Randomization was stratified for the presence of DMARDS approved for use in the study (Sulfasalazine, Methotrexate and Hydroxychloroquine).
Etanercept 25mg or placebo was administered sc twice per week at a fixed dose for 12 weeks in patients with active AS who met eligibility criteria. There was no provision for dose modification of the study drug other than skipping administration of a dose of study drug. Patients who developed a Grade 3 or 4 adverse event thought to be related to the study treatment could suspend study drug for one week but if 4 consecutive doses of study drug were missed, the subject was withdrawn from study.
Study Population
Men and women, outpatients, between 18 and 70 years of age with AS, as defined by the modified New York Criteria for Ankylosing Spondylitis which was active at the time of enrollment as defined by:
- visual analog
scale (VAS) values ³ 30 (on a scale of 0–100) for the following
parameter:
- Average of
duration and intensity of morning stiffness
PLUS VAS values ³ 30
for 2 of the following 3 parameters:
- patient global
assessment
- average of VAS
values for nocturnal back pain and total back pain
- average of 10
questions on the BASFI.
Excluded were subjects with:
Complete Ankylosis of the spine
use of DMARDS other than Sulfasalazine, Methotrexate or Hydroxychloroquine
Previous Receipt of Etanercept or other TNFa-blocking agents
Dose of prednisone > 10mg/d or changed within 2 weeks of baseline evaluation
Dose of NSAIDS changed within 2 weeks of baseline or multiple NSAIDS in use
Significant abnormality in chemistry or hematology profiles
Significant concurrent medical conditions or events
Primary Efficacy Outcome
The primary efficacy outcome was determined at 12 weeks of treatment using the following ASAS Response Criteria
ASAS Response Criteria (ASAS 20)
already defined in study 016.0037 on page 6 at 12 weeks.
Secondary Efficacy Outcomes:
Secondary
Efficacy Outcomes included:
the ASAS
Response Criteria of 50% and 70% improvement at week 12 which were defined in
study 016.0037 on page 6
-Additional
analysis of ASAS response at Week 12
Frequency
and time to the ASAS definition of partial remission defined on page 7
Individual
components of the ASAS Instrument
Components of Other AS Instruments
patients could be discontinued from study treatment for lack of efficacy defined as failure to improve 3of 4 ASAS Response Criteria by 10% or more at week 8 (and 12) and at early termination visit.
Clinical and Laboratory Evaluations
Patients were assessed for both efficacy and safety at weeks 2,4,8,12 (or Early Termination). Safety was additionally assessed at the 15-day follow-up. All components of the ASAS Response Criteria as well as Assessor global score and blinded joint assessment were performed at these times. Physical examination including vital signs as well as measurements of spinal mobility were performed at those visits. Laboratory evaluation including Chemistry profile, urinalysis were scheduled to be performed at baseline, weeks 4 and 12. ESR and C-reactive Protein were to be performed with each efficacy/safety visit except for the 15 day follow-up. All laboratory tests except ESR were performed centrally and all results were withheld from the investigator until after the study was un-blinded
Statistical Analyses
Primary efficacy analysis
The primary efficacy population was the modified Intention to Treat population which was defined as all subjects randomized and who received at least one dose of study medication
The primary efficacy endpoint was
the number of responders at week 12 as determined
by the ASAS response criteria for
improvement in AS. The etanercept and placebo groups were compared by using the
Mantel-Haenszel test stratified by presence or absence of concomitant DMARDs.
All patients who withdrew before 12 weeks were considered non-responders for
this endpoint.
Secondary analyses:
Secondary endpoints were the number of
responders at week 12 as determined by the
ASAS 50% and 70% response criteria. These
endpoints were analyzed as described
previously for the primary efficacy endpoint
(Fisher’s exact test was substituted if more
appropriate). An additional analysis of ASAS
responses at week 12 was performed by
classifying patients on a scale of 1 to 4
according to their highest response status with
respect to ASAS 20%, 50%, and 70% endpoints.
Values assigned were 1 for ASAS 20%
non-responders, 2 for ASAS 20% responders, 3
for ASAS 50% responders, and 4 for
ASAS 70% responders. Scores were compared
between the 2 treatment groups by using
the stratified rank test. Changes (and
percentage changes) from baseline in the individual
components of the ASAS Working Group criteria
for response (VAS patient global
assessment, VAS total and nocturnal pain,
BASFI, and BASDAI), spinal mobility
measures, VAS physician global assessment,
complete joint assessment, evaluation of hip
involvement, and laboratory assessments of
inflammation were compared between the
2 treatment groups by using the stratified
rank test. The stratified rank test was
performed using the Cochran-Mantel-Haenszel
test with the modified ridit option.
Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis
The PK-PD relationship between etanercept
serum concentrations and clinical efficacy
was evaluated in this patient population.
Major Protocol Amendments
There were no major
protocol amendments
Study Results
The study was conducted entirely in 8 European Countries with 14 centers participating.
Patient Disposition
A total of 84 patients were enrolled in the
study and all 84 patients received study drug.
Eighty-two (82) patients completed 12 weeks
of treatment. Two patients, both in the etanercept arm withdrew from the study.
1 patient did not meet disease activity eligibility criteria and the other
withdrew his consent (Table 34).
Table 34 Study Completion at 12 weeks
Study Completion Status at 12 Weeks |
||
|
Placebo |
Etanercept |
|
(N = 39) |
(N = 45) |
Patient Status |
n (%) |
n (%) |
Completed 12 weeks in study |
39 (100) |
43(96) |
Discontinued study due to: |
|
|
Lack of disease activity |
0 (0) |
1 (<1) |
Patient refusal |
0 (0) |
1 (<1) |
Patient Demographics
The mean age of study participants was approximately 43 and was 4 years older in the etanercept recipients. The study excluded pediatric patients and there was an upper age limit of 70 years of age. The mean weight of participants was 74 kg for placebo recipients and 76 kg for etanercept recipients.
Approximately 78% of the participants were male which corresponds to the higher prevalence of AS in men. More than 93% of the participants were Caucasian, minority participation was low and similar in both arms (Table 35).
Table 35 Population Demographics
Demographic Characteristics |
||
|
Placebo |
Etanercept |
Characteristic |
N = 39 |
N = 45 |
Mean age in years |
40.7 |
45.3 |
Male (n [%]) |
30(77) |
36(80) |
Race (n [%]): |
|
|
Caucasian |
37(95) |
42 (93) |
Asian |
0 (0) |
1 (2) |
Other |
2 (5) |
2 (4) |
Mean weight (kg) |
73.7 |
76.1 |
Baseline Disease History
The mean duration of ankylosing
spondylitis was higher in the etanercept recipients than in the placebo
recipients. The percentage of HLA-B27 antigen positivity was similar in both
arms. The majority of participants had a history of NSAIDS and DMARDS usage
although the percentage was higher for both in the etanercept recipients. A
similar percentage of participants in both arms had a history of concomitant
corticosteroid usage. Approximately 40% of participants in both arms were on
concomitant DMARDS. Sulfasalazine was the most common DMARD in both arms (Table 36).
Table 36 Baseline Disease History
Baseline Disease History |
||
|
Placebo |
Etanercept |
Mean duration of AS in years |
10 |
15 |
Median duration of AS in years |
7 |
14 |
HLA B-27 positive |
34 (87) |
38 (88) |
Prior NSAIDS |
36(92) |
44 (98) |
Prior DMARDS |
24 (62) |
34 (76) |
Concomitant therapy baseline (n [%]): |
|
|
Any DMARD |
16 (41) |
16 (36) |
Sulfasalazine (SSZ) |
11 (28) |
11 (24) |
Methotrexate (MTX) |
5 (13) |
6 (13) |
Hydroxychloroquine (HCL) |
1 (3) |
0 |
Oral Corticosteroids |
6 (15) |
7 (16) |
Baseline
Disease Activity
The level of baseline disease activity
as measured by the 4 ASAS domains was of moderate intensity and was well
balanced between the two study arms (Table 37).
Spinal mobility measurements demonstrated less mobility in the etanercept arm
especially in the occiput to wall measurement (Table 37).
The remainder of baseline measurements of AS components, the physician global
assessment, and the acute phase reactants indicated moderate intensity that was
balanced across the study arms (Table 37).
Table 37 Baseline Disease Activity
Baseline Disease Activity |
|
||
|
Placebo |
Etanercept |
|
Characteristic
|
N = 39 |
N = 45 |
|
Mean baseline ASAS components (range): |
|
|
|
Patient global assessment |
63(31-86) |
66 (26-100) |
|
Nocturnal and total back pain |
56 (10-100) |
60
(0-100) |
|
BASFI |
57 (18-82) |
60 (14-100) |
|
Inflammation |
59 (36-87) |
61 (27–100) |
|
Mean baseline other study AS components |
|
|
|
Physician Global Assessment
|
58 (15-100) |
56(18-87) |
|
Erythrocyte Sedimentation Rate
|
33 (4-100) |
31(1-108) |
|
C-Reactive Protein, mg/L
|
24 (4-227) |
19(4-63) |
|
Chest Expansion Score, cm
|
3.9 (1-11) |
3.3( .5-8) |
|
Schober’s Test, cm
|
12.8 (11-16) |
12.2 (11-15) |
|
Occiput to Wall Measurements
|
4.6 (0-21) |
7.3 (0-23) |
Extra-Spinal
Inflammatory Signs/Symptoms
There was some imbalance between the study arms in terms of extra-spinal inflammatory signs and symptoms. The percentage of participants with ocular inflammation, uveitis, urethritis and psoriasis was higher among the etanercept participants than in the placebo (Table 38). The only extra-spinal factors that appeared to be well balanced between the two arms was a history of inflammatory bowel disease and a sexually transmitted disease (Table 38).
Table 38 Extra-Spinal Articular Inflammatory Symptoms
Extra-Spinal/Articular Inflammatory
Symptom |
Placebo n/N
% |
Etanercept n/N % |
Ocular Inflammation |
5/39 (13) |
9/45 (20) |
Non-Infectious Conjunctivitis |
2/39 (5) |
4/45 (9) |
Uveitis or Iritis |
6/39 (15) |
13/45 (29) |
Crohns Disease or Ulcerative Colitis |
2/39(5) |
3/45 (7) |
Urethritis |
0/39 (0) |
3/45 (7) |
STD |
0/39 (0) |
0/45 (0) |
Psoriasis |
3/39 (8) |
10/45 (22) |
Primary Efficacy Analysis
The primary
efficacy endpoint of this study was the achievement of an ASAS 20 at week 12
using the ASAS Working Group Response Criteria. 60% of etanercept recipients
versus 23% of placebo recipients achieved the primary endpoint which was statistically significant difference with a p
value of 0.0008 (Table
39).
Table 39 Primary Endpoint Study
Primary Endpoint: ASAS 20 at 12 weeks |
|
||
Number (%) Achieving ASAS 20 Response at
Week 12 |
|||
|
Placebo |
Etanercept |
|
Parameter |
N = 39 |
N = 45 |
P-value* |
ASAS 20 at 12 weeks |
9 (23) |
27(60) |
0.0008 |
* P-value determined by Cochran-Mantel-Haenszel row means test. |
Secondary
Efficacy Analysis
In this study, the secondary
efficacy analysis includes all the remaining AS measurements including: ASAS 50
and 70 at 12 weeks, highest ASAS response at 12 weeks, achievement of partial
remission, analysis of individual components of the ASAS response criteria,
spinal mobility parameters, peripheral tender and swollen joints, acute phase
reactants, and physician global assessment.
ASAS 50/70 at 12
weeks
Higher levels of response using the ASAS Response Criteria were analyzed. The superior performance of etanercept was again demonstrated in the ASAS 50 measurement with a numerical difference of 49% versus 10% and a p value favoring etanercept of 0.0002 (Table 40). Although the etanercept arm had a numerically higher ASAS 70 response than placebo at 24% versus 10%, this value did not achieve statistical significance with a p-value of 0.0973 at 12 weeks (Table 40). The explanation for this failure to achieve statistical significance for the ASAS 70 determination is most likely attributable to the small numbers involved.
Table 40 Secondary Endpoints ASAS 20, 50, 70: 2/12 weeks
Secondary Endpoints: ASAS 20/50/70 at
12/24 weeks |
|||
|
Placebo |
Etanercept |
|
Parameter |
N = 39 |
N =45 |
P-value*
|
ASAS 20 (n [%]) at: |
|
|
|
2 weeks |
3 (8) |
24 (53) |
0.0000 |
12 weeks |
9 (23) |
27 (60) |
0.0008 |
ASAS 50 (n [%]) at: |
|
|
|
2 weeks |
1 (3) |
11 (24) |
0.0046 |
12 weeks |
4 (10) |
22 (49) |
0.0002 |
ASAS 70 (n [%]) at: |
|
|
|
2 weeks |
0 (0) |
6 (13) |
0.0183 |
12 weeks |
4 (10) |
11 (24) |
0.0973 |
* P-value determined by
Cochran-Mantel-Haenszel row means test. |
|
Highest ASAS
Response at week 12
Analysis of highest ASAS response
achieved indicates that among the patients whose highest response was ASAS 20,
that is they never achieved ASAS 50 or ASAS 70, the numbers and percentages are
similar in both study arms. Higher proportions of etanercept treated patients
achieved higher level (ASAS 50, 70) responses (Table 41).
Table 41 Secondary Endpoint: Highest ASAS Responses at weeks
12
Secondary Endpoint: ASAS Highest level of
Response |
|||
|
|
Placebo |
Etanercept |
Time point |
Highest level of response |
N = 39 |
N = 45 |
Week 12 |
ASAS 20 non-responder |
30 (77) |
18(40) |
|
ASAS 20 responder |
5 (13) |
5 (11) |
|
ASAS 50 responder |
1 (3) |
14 (31) |
|
ASAS 70 responder |
3 (8) |
8 (18) |
Partial Remission
As previously indicated, partial
remission was defined as achievement of a disease activity level <20 on VAS
in all 4 ASAS domains. In this study, although the etanercept recipients have
numerically higher partial remission rates than placebo, especially early in
the study (2weeks), the differences do not reach statistical significance (Table 42).The explanation for this is not known but probably
relates to the small number of patients achieving partial remission in both
arms.
Table 42 Secondary Endpoint: Achievement of Partial
Remission
Secondary Endpoint: ASAS Partial
Remission |
|||
|
Placebo |
Etanercept |
|
|
N = 39 |
N = 45 |
|
Time point |
n (%) |
n (%) |
P-value* |
Week 2 |
0 (0) |
4 (9) |
0.0573 |
Week 12 |
4 (10) |
8 (18) |
0.3457 |
Any time during the study |
5 (13) |
12 (26) |
0.1246 |
* P-value determined by Cochran-Mantel-Haenszel row means test. |
Individual
Components of ASAS Response Criteria
Response data corresponding to each of the components of the 4 domains of the ASAS Response Criteria were individually analyzed. The components analyzed using a Visual Analog Scale were: patient global assessment, average of nocturnal back pain and total back pain, the average of the 10 questions of the BASFI (function) and the last two questions of the BASDAI (inflammation). The results of this analysis indicated that for each component, etanercept recipients had a statistically significantly greater improvement than placebo recipients (Table 43).
Table 43 ASAS Individual Components
Individual ASAS Components
|
|||||
Mean Values and Percent Improvement from Baseline |
|||||
|
|
|
|||
|
Mean Values |
Percent Improvement from Baseline |
|||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Parameter
|
N = 39 |
N = 45 |
N = 39 |
N = 45 |
|
Patient’s Global Assessment
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
Baseline |
63 |
66 |
|
|
|
12 weeks |
54 |
38 |
13 |
37 |
0.0107 |
Average of Nocturnal Back Pain/ Total
Back Pain |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline
|
56 |
60 |
|
|
|
12 weeks |
51 |
31 |
6 |
43 |
0.0003 |
BASFI |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline
|
57 |
60 |
|
|
|
12 weeks |
54 |
40 |
3 |
35 |
0.0003 |
BASDAI |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline
|
63 |
68 |
|
|
|
12 weeks |
53 |
36 |
16 |
43 |
0.0025 |
Spinal
Mobility Parameters
Assessment for Spinal Mobility using the modified Schober’s test, chest expansion and occiput to wall measurement and these data are presented in (Table 44). In this study, although in all three measurements, the percentage of improvement in the etanercept recipients was consistently numerically higher than placebo, only in the Schober’s test did that superiority reach statistical significance at12 weeks (Table 44). Measurement of chest expansion which is the spinal mobility parameter selected for the DCART 20 (Table 17) demonstrated the least significant p-value of the three. The explanation for these spinal mobility parameter data is not known but the relatively short duration of treatment(12 weeks) and the small number of patients are likely contributants.
Table 44 Other Endpoints: Spinal Mobility Parameters
Spinal Mobility Parameters: |
||||||
Mean Values and Percent Improvement from Baseline |
||||||
|
Mean Values (cm) |
Percent Improvement from Baseline* |
||||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
|
Parameter |
N = 39 |
N = 45 |
N = 39 |
N = 45 |
P-value† |
|
Modified Schober’s test |
|
|
|
|
|
|
Baseline
|
2.8 |
2.2 |
|
|
|
|
12 weeks |
2.7 |
2.7 |
-1.3 |
36 |
0.0085 |
|
Chest expansion |
|
|
|
|
|
|
Baseline
|
3.9 |
3.3 |
|
|
|
|
12 weeks |
4.1 |
3.8 |
9 |
30 |
0.8695 |
|
Occiput-to-wall Measurement |
|
|
|
|
|
|
Baseline
|
4.6 |
7.3 |
|
|
|
|
12 weeks |
4.0 |
6.2 |
7 |
13 |
0.0650 |
|
* Patients with a score of
zero at baseline were not included in the analysis of percent improvement
from |
||||||
baseline. The number of
patients with a zero baseline score varied, depending on the parameter of
interest. |
||||||
† P-value determined by
Cochran-Mantel-Haenszel row means test with Modridit option on percent |
||||||
Improvement from baseline. |
|
|
|
|
||
Peripheral
Tender and Swollen Joint Counts
As was seen in the previously
described study, the response rates of peripheral tender and swollen joints are
lower than those of other domains. treatment
difference favoring etanercept is suggested for both tender and swollen joints,
especially for tender joints (Table 45). Neither measured difference
achieves statistical significance, however. Again, the likely explanations are
the small study population and the paucity of any peripheral joint involvement,
especially swollen joints among this population. The median values for number
of swollen joints was 0 and 3 for tender joints in both arms at baseline. The
values seen in (Table
45) represent those individuals with swollen and
painful joints at baseline.
Table 45 Other Endpoints: Peripheral Tender and Swollen
Joint Counts
Peripheral Tender and Swollen Joint
Counts |
||||||||
Mean Values and Percent Improvement from
Baseline |
||||||||
|
Mean Values |
Percent Improvement from Baseline* |
||||||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
|||
Parameter
|
N = 39 |
N = 45 |
N = 39 |
N =45 |
P-value† |
|||
Tender joints |
|
|
|
|
|
|||
Baseline |
9.7 |
6.6 |
|
|
|
|||
12 weeks |
8.3 |
3.5 |
14 |
47 |
0.0613 |
|||
Swollen joints |
|
|
|
|
|
|||
Baseline |
5.1 |
3.6 |
|
|
|
|||
12 weeks |
5.3 |
2.3 |
-4 |
36 |
0.4095 |
|||
* Patients with a count of
zero at baseline were not included in the analysis of percent improvement
from |
||||||||
baseline. The number of
patients with a zero baseline score varied, depending on the parameter of
interest. |
||||||||
† P-value determined by
Cochran-Mantel-Haenszel row means test with Modridit option on percent |
||||||||
Improvement from baseline. |
|
|
|
|
|
|||
Acute Phase
Reactants
At baseline the measured acute phase reactants in both arms of the study were elevated with mean ESR/CRP for etanercept and placebo of 31/19 and 33/24 and median ESR/CRP for etanercept and placebo of 27/15 and 26/10 (Table 46). During the course of the study, the median values for both ESR and CRP dropped significantly among the etanercept recipients compared to placebo (Table 46).
Table 46 Other Endpoints: Acute Phase Reactants
Acute Phase Reactants |
|||||||
Median Values and Percent Improvement from Baseline |
|||||||
|
Median Values |
Percent Improvement from Baseline* |
|||||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
||
Parameter
|
N = 39 |
N = 45 |
N = 39 |
N =45 |
P-value† |
||
ESR (mm/hr)‡ |
|
|
|
|
|
||
Baseline |
26 |
27 |
|
|
|
||
12 weeks |
29 |
6 |
0 |
80 |
<0.0001 |
||
CRP (mg/dL)** |
|
|
|
|
|
||
Baseline |
9.7 |
15.4 |
|
|
|
||
12 weeks |
11.7 |
4.0 |
-20 |
70 |
<0.0001 |
||
* Patients with a score of
zero at baseline were not included in the analysis of percent improvement
from |
|||||||
baseline. Some patients in
both groups had a baseline score of zero for ESR, but no patients in either |
|||||||
group had a baseline score
of zero for CRP. |
|
|
|
||||
† P-value determined by
Cochran-Mantel-Haenszel row means test with Modridit option on percent |
|||||||
improvement from baseline. |
|
|
|
|
|||
‡ Erythrocyte
sedimentation rate (ESR) normal range: 1–17 mm/hr for men; 1–25 mm/hr for
women. |
|||||||
**C-reactive protein (CRP)
normal range: 0–1.0 mg/dL. |
|
|
|
||||
Physician Global
Assessments
The Physician Global Assessments performed in this study indicated that etanercept recipients had greater improvement from baseline than did placebo. This treatment difference was statistically significant (Table 47).
Table 47 Physician Global Assessments
Physician Global Assessments |
|||||||
Mean Values and Percent Improvement from Baseline |
|||||||
|
Mean Values |
Percent Improvement from Baseline |
|||||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
||
Parameter
|
N = 39 |
N = 45 |
N =39 |
N = 45 |
P-value* |
||
Assessor’s Global
Assessment
|
|
|
|
|
|
||
Baseline
|
57.5 |
55.7 |
|
|
|
||
12 weeks |
46 |
32.6 |
20 |
39 |
0.0321 |
||
* P-value determined by Cochran-Mantel-Haenszel row means test with Modridit option on percent |
|||||||
Improvement from baseline. |
|
|
|
|
|||
Overview
of Adverse Events
Approximately 60% of patients in
both study arms experienced one or more adverse events during the 12 weeks of
study and 15 days of follow-up (Table 48). Overall, injection site
reactions, injection site ecchymosis, and asthenia were more prevalent in
etanercept recipients than in placebo recipients. In this study, infections
occurred with similar incidence in both study arms. Study drug dose
modification was accomplished by skipping administration of a scheduled dose.
Table 48 Adverse Events in ³ 5% of Patients
Adverse Events of
All Intensities in ³5% of Patients in Either Treatment Group |
||
|
Proportions of Patients (n [%]) |
|
|
Placebo |
Etanercept |
Event |
N = 39 |
N = 45 |
Any adverse event |
24 (62) |
25 (56) |
Infections |
13(33) |
16(36) |
Injection site reaction |
6 (15) |
15 (33) |
Injection site ecchymosis |
4 (10) |
8 (18) |
Headache |
5 (13) |
6 (13) |
Accidental injury |
2(4) |
0 (0) |
Diarrhea |
2(5) |
2 (4) |
Rash |
0 (0) |
2 (4) |
Dizziness |
1 (3) |
1 (2) |
Rhinitis |
9 (7) |
8 (6) |
Abdominal pain |
2 (5) |
1 (2) |
Nausea |
4 (10) |
3 (7) |
Asthenia |
1 (3) |
5 (11) |
There was one serious adverse event, a myocardial infarction in one etanercept patient who also experienced the only Grade 3 Laboratory Abnormality. There were no withdrawals for safety reasons. The number of Grade 3 Adverse Events was low in both arms but was higher in the etanercept arm (Table 49).
Table 49 Tabulation
of Important Safety Outcomes
Safety Outcomes
|
Placebo N=39 n/N % |
Etanercept N=45 n/N % |
Serious Adverse Events
|
0 (0) |
1* (2) |
Withdrawals
for Safety |
0 (0) |
0 (0) |
Grade 3/4
Adverse Events/ Infections |
2 (5) |
4 (9) |
Grade 3/ 4
Abnormal Laboratory |
0 (0) |
1* (2) |
*The same patient
Serious Adverse
Events
There were no deaths during the study. There
was only one serious adverse event occurring during the conduct of this trial.
The patient a 51 year old man who was a etanercept recipient experienced a
acute myocardial infarction. He received a coronary artery bypass and completed
the study (Table
50).
Table 50 Serious Adverse Events
Patient no. |
Sex/Age |
D/C Date |
Cause |
Grade |
Comments |
Placebo |
|
|
|
|
|
|
|
|
|
|
|
Etanercept |
|
|
|
|
|
012-335 |
M/51 |
81 |
Myocardial
Infarction |
3 |
Completed
Study after CABG |
Infections
The numbers of infections in both study arms was similar. Upper respiratory tract infection was numerically the most common infection in both arms occurring in 3 placebo recipients and 5 etanercept. Flu syndrome was more common in placebo compared to etanercept at 4 to 1, and periodontal abscess was more common in etanercept patients at 3 to 0. Otherwise all infections occurred with nearly identical incidence between the two arms (Table 51).
Table 51 Infections of All Intensities in ³ 5% of Patients
Treatment Emergent Infections in Either Treatment Group |
||
|
Proportions of Patients (n [%]) |
|
|
Placebo |
Etanercept |
Event |
N = 39 |
N = 45 |
Any infection |
13 (33) |
16 (36) |
Any infection except URI |
10 (26) |
12 (27) |
Upper respiratory infection |
3 (8) |
5
(10) |
Flu syndrome |
2 (5) |
1
(2) |
Grade
3 and 4 Adverse Events not considered SAE
There were no Grade 4 Adverse
Events in either study arm. The Grade 3 Adverse Events occurring in the
etanercept recipients included one episode of asthenia, one of severe headache,
one accidental bone fracture and the grade 3 liver function test abnormalities
that occurred in the patient who experienced the myocardial infarction (Table 52). These liver function test abnormalities resolved
with the discontinuation of the patient’s NSAIDS.
Table 52 Grade 3/4 Adverse Events/Infections Not SAE
Patient no. |
Sex/Age |
Cause |
Grade |
Placebo |
|
|
|
004-99 |
M/61 |
BACK PAIN |
3 |
012-333 |
M/27 |
Hypoglycemia |
3 |
Etanercept |
|
|
|
004-98 |
M/40 |
Asthenia
|
3 |
009-245 |
M/43 |
Headache |
3 |
009-247 |
F/51 |
Bone
FX |
3 |
012-335 |
M/51 |
Abn LFTS |
3 |
Efficacy
In study CSR-47687, etanercept 25mg sc biw was superior to placebo in the achievement of ASAS 20 Response Criteria at 12 weeks in patients with active Ankylosing Spondylitis. The treatment difference is an absolute 37%, which is statistically significant at a level of p= 0.0008. At ASAS 50, etanercept also achieved statistical superiority to placebo but not at ASAS 70.
All four domains of the ASAS Response Criteria supported the superiority of etanercept. The fifth remaining ASAS Working Group recommended domain, Spinal mobility was measured. In this study, only the modified Schober’s test determined a statistically significant improvement compared to placebo at 12 weeks. As in Study 016.0037, chest expansion was the spinal mobility parameter that evidenced the least response. Etanercept recipients experienced improvement in numbers of tender and swollen peripheral joints but these improvements were not statistically significant. Acute phase reactants ESR and CRP were statistically improved in etanercept recipients compared to placebo recipients.
Summary of Study CSR: 016.0626
Study Title:
“Anti-Tumor Necrosis Factor (TNFR:Fc)
in Ankylosing Spondylitis (A Phase 2 Trial)”
Study Design:
Study
016.0626 was a randomized, single center, double blinded, placebo controlled
phase 2 study of etanercept versus placebo in conjunction with the use of
standard medication for AS in 40 patients with active ankylosing spondylitis.
Subjects were randomly assigned to one of two treatment arms: etanercept 25mg
sc biw or placebo on a 1:1 basis. Subjects were treated for a total of 16 weeks
with a primary endpoint of 20% improvement from baseline in 3 of 5 elements of
pre-specified response criteria (with one of the improved measures being spinal
pain or morning stiffness) and without worsening in the remaining 2 elements.
For patients without joint swelling (one of the 5 measured elements) at
baseline, improvement was required in 3 of the remaining 4 elements without
concurrent worsening in the remaining one.
Dosing and Dosing Modification:
Etanercept was administered at a dose of 25
mg SC twice weekly. There was no provision for dose modification other than
skipping dosage.
Study Population
Men
and Women, outpatients, 18 years or older, with AS, as defined by the modified
New York Criteria for Ankylosing Spondylitis, Active AS defined by the presence
of morning stiffness ³ 45 minutes, inflammatory
back pain, patient and physician global assessment of moderate or more severe
disease activity, receiving a stable dose of one of the following regimens for
at least one month prior to study without adequate disease control: NSAID, oral
glucocorticoids £ 10mg/d, Sulfasalazine,
Methotrexate, combination of Methotrexate and Sulfasalazine, azathioprine or
6-mercaptopurine.
Excluded were:
Primary Efficacy
Outcome
There were 5 pre-specified measures
considered in the primary efficacy outcome (AS Response Criteria).
·
Patient global assessment: rated on a 5-point scale (1 =
none, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe) over the past week.
Improvement was defined as a decrease of 1. Worsening was defined as an
increase of 1.
·
Nocturnal spinal pain: assessed on a 100 mm VAS of spinal pain at night over the
past
week. Extremes of the scale were labeled as “none” and “very severe.”
Improvement
was defined as a 20% decrease in number of millimeters on the scale and an
increase of 20% over baseline was classified as worsening.
ability
to perform specific tasks as measured by VAS with extremes labeled “none” and
“very severe.” Improvement was defined as a 20% decrease in the combined mean
functional index score. Worsening was defined as an increase of 20%.
Secondary Efficacy Endpoints:
spinal
pain, duration of morning stiffness, BASFI, and swollen joint score examined
independently.
patients
rate from 1 (indicating strong disagreement with the statement) to 7
(indicating
strong agreement); the average of the 9 components subjected to analysis.
Ad Hoc Analyses
Responses in
clinical criteria at 50 and 70% improvement levels were determined, with 20%
worsening maintained as the definition of worsening.
Statistical Analyses
The primary efficacy analysis was an
intent-to-treat analysis that included all patients who were randomized and
received study drug. Patients who discontinued study drug prior to the Day 112
assessment were considered non-responders. The 20% response criteria rates for
improvement in AS were compared between the etanercept and placebo groups on
Day 112 using Fisher’s exact test (two tailed). Analyses at other time points
were performed in a similar manner and were considered supplemental. Continuous
variables, such as the individual components of the response criteria for
improvement in AS, and change and percent change from baseline, were compared
between placebo and etanercept using Wilcoxon’s test. Values at the last
available visit were used for the last observation carried forward (LOCF)
analysis, for patients with missing data on Day 112. A supplemental analysis
based on data only from patients who completed Day 112 was also performed for
the primary endpoint.
Synopsis of the Study Results other than Efficacy Determinations
Efficacy Determinations
Primary Efficacy
Analysis
The primary efficacy endpoint for this study was the achievement of a 20% response at week 16 using the 5 pre-specified criteria listed above as, AS Response Criteria. At 16 weeks, 75% of etanercept recipients versus 25% of placebo recipients had achieved this primary endpoint, a statistically significant difference with a p-value of 0.01 (Table 53).
Table 53 Primary Endpoint
Primary
Endpoint: Number (%) Achieving 20% AS Response Criteria |
|||
|
Placebo |
Etanercept |
P-value |
Time point |
N=20 |
N=20 |
|
Week 12 |
5 (25) |
14 (70) |
0.01 |
Week 16 |
5 (25) |
15 (75) |
0.01 |
Ad Hoc Analysis
This study was commenced prior to
the publishing of the ASAS Working Group Response Criteria. The ASAS Response
Criteria were applied to the data, however as an ad hoc analysis. in addition, a 50% and 70% response
analysis using the pre-specified criteria for this study was performed. Both
will be discussed.
The ASAS Working Group Response
Criteria were the same as those used in the two prior studies. Modification was
required because in this study patient global assessment was scored on a 1-5
scale rather than by VAS and inflammation was represented by the duration of
morning stiffness in minutes without assessment of intensity, not by VAS. The
following adjustments were performed to convert to the ASAS Response Criteria.
durations > 120
minutes to 100 and calculating durations < 120 minutes as 5/6 times the
duration in minutes.
Additional endpoints that were evaluated
using the modified ASAS definition of response
included a 50% and 70% response criteria for
improvement, with deterioration defined
the same as for the 20% response criteria.
Applying the ASAS Response Criteria with the
modifications as described above to the data, at 16 weeks the etanercept
recipients achieve an ASAS 20 endpoint of 85% versus 25% for the placebo
recipients, a highly statistically significant difference with a p-value of
0.0003 (Table 54). While both the AS
20 response criteria pre-specified for this study
and the modified ASAS Response Criteria indicate superiority of etanercept over
placebo, the measured treatment difference is greater using the ASAS Response
Criteria.
Table 54 Ad Hoc Analysis: ASAS 20, 50, 70
ASAS 20/50/70 for Study 0626 |
|
||||
|
Placebo |
Etanercept |
|
|
|
Parameter |
N = 20 |
N = 20 |
P-value*
|
|
|
ASAS 20 (n [%]) at: |
|
|
|
|
|
12 weeks |
5 (25) |
13 (65) |
0.02 |
|
|
16 weeks |
5(25) |
17 (85) |
0.0003 |
|
|
ASAS 50 (n [%]) at: |
|
|
|
|
|
12 weeks |
2 (10) |
11 (55) |
0.01 |
|
|
16weeks |
4 (20) |
9 (45) |
0.18 |
|
|
ASAS 70 (n [%]) at: |
|
|
|
|
|
12 weeks |
0 (0) |
2 (10) |
0.49 |
|
|
16 weeks |
3 (15) |
5(25) |
0.69 |
|
|
|
* P-value determined by Fisher’s exact test |
||||
Conversely, comparing the 50%
responses of the pre-specified criteria in (Table 55) with
the ASAS 50% values in (Table 54), the treatment difference
is only statistically significant in the AS response
criteria. The AS 50 Response
Criteria and the ASAS Response Criteria achieve identical results in the 70%
level for the etanercept group.
Table 55 Secondary Endpoints: AS 50/70% Response
Secondary
Endpoint: Number (%) Achieving 50% and 70% Response Criteria |
|||
|
Placebo |
Etanercept |
P-value |
50%
Improvement |
N=20 |
N=20 |
|
Week 12 |
2 (10) |
14 (70) |
0.01 |
Week 16 |
5 (25) |
15 (75) |
0.04 |
70%
Improvement |
|
|
|
Week 12 |
2 (10) |
2 (10) |
1.00 |
Week 16 |
2 (10) |
5 (25) |
0.41 |
* P-value determined by Fisher’s exact test |
Individual
Components AS Response Criteria
The 5 components of the AS Response Criteria resemble the 4 domains recommended for assessment by of the ASAS Working Group. The major differences between the two systems are: 1) nocturnal back pain versus average of nocturnal back pain /total back pain in ASAS 2) intensity as well as duration of morning stiffness in ASAS and 3) the inclusion of swollen joints in the AS Response Criteria.
Etanercept recipients achieved statistically significantly greater improvement than placebo recipients as measured by 4 of the 5 components of the AS Response Criteria (table 56). The component examining swollen peripheral joints demonstrated numerically higher response in etanercept recipients compared to placebo but this difference was not statistically significant. One possible explanation for the lack of response for swollen joints is the paucity of swollen joints in this disease.
Table 56 Secondary Endpoints: Individual Components of AS Response Criteria
Individual Components of AS Response
Criteria |
|||||
Mean (median) Values and Percent Improvement from Baseline |
|||||
|
|
Mean(median) |
|||
|
Mean (median) Values |
Percent Improvement from Baseline |
|||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Parameter
|
N = 139 |
N = 138 |
N = 139 |
N = 138 |
|
BASFI |
Placebo |
Etanercept |
Placebo |
Etanercept |
|
Baseline |
63 (64) |
63 (66) |
|
|
|
Week 12 |
56 (57) |
35 (32) |
10.5 (-4) |
42.2 (-41) |
0.01 |
Week 16 |
56 (57) |
36 (29) |
7.2 (7) |
48.7 (-47) |
0.0003 |
Nocturnal back pain † |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline |
62 (65) |
60 (62) |
|
|
|
Week 12 |
55 (56) |
33 (26) |
-2.8 (-11.6) |
-55.5(-68) |
0.0008 |
Week 16 |
56 (61) |
34 (26) |
-14.4 (-22) |
-61.2 (-67) |
0.001 |
Patient global assessment |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline |
56 (59) |
52 (50) |
|
|
|
Week 12 |
53 (53) |
35 (29) |
-7.1 (0.0) |
-28 (-33) |
0.01 |
Week 16 |
55 (55) |
36 (31) |
-11 (0.0) |
-28 (-33) |
0.02 |
Duration of morning stiffness |
Placebo |
Etanercept |
Placebo |
Etanercept |
P-value |
Baseline |
64 (65) |
61.4 (60) |
|
|
|
Week 12 |
53 (49) |
32.8 (21) |
(-17) |
(-75) |
0.01 |
Week 16 |
57 (58) |
33.4 (26) |
(-18) |
(-76) |
0.01 |
Swollen joint score |
|
|
|
|
|
Baseline |
3.2 (1.0) |
3.7 (0.0) |
|
|
|
Week 12 |
3.4 (0.5) |
1.6 (0.0) |
-8.4 (-38) |
-74 (-77) |
0.09 |
Week 16 |
3.7 (0.5) |
1.6 (0.0) |
-14 (0) |
-47(-63) |
0.3 |
Assessments of spinal mobility
utilized the same parameters as were used in both phase 3 studies. In this
study, however, a statistically significant difference was demonstrated between
etanercept and placebo at 16 weeks in two components and a strong trend for the
third (the p-value of chest expansion was 0.0505 technically not statistically
significant) (Table
57). At 12 weeks, only occiput to wall achieved
statistical significance. It might be concluded from this data that receipt of
etanercept is associated with statistically significant improvement in spinal
mobility parameters when the measurements are taken 16 weeks into therapy but
not necessarily at 12 weeks. Additionally, it would appear that chest expansion
in this study was the least responsive.
Table 57 Other Endpoints: Spinal Mobility Parameters
Spinal Mobility Mean (Median) Values and
Percent Change Baseline to Week 16 |
||||||
|
|
Actual Values |
% change from baseline |
|
||
|
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
Parameter
|
n = 20 |
n = 20 |
n = 20 |
n = 20 |
P-value* |
|
Chest expansion † |
|
|
|
|
|
|
|
Baseline |
3.0 (3.1) |
2.9 (2.6) |
- |
- |
|
|
Week 12 |
3.1 (3.0) |
3.8 (4.0) |
12.4 (0.0) |
66.9 (20.0) |
0.0994 |
|
Week 16 |
3.0 (2.9) |
3.6 (3.5) |
6.0 (0.0) |
36.6 (22.5) |
0.0505 |
Modified Schober's test |
|
|
|
|
|
|
|
Baseline |
3.3 (3.5) |
2.5 (2.5) |
- |
- |
|
|
Week 12 |
3.2 (3.5) |
2.7 (2.8) |
-4.0 (0.0) |
15.8 (16.7) |
0.0578 |
|
Week 16 |
3.2 (3.4) |
2.8 (3.4) |
-5.6 (-2.4) |
21.1 (14.2) |
0.0416 |
Occiput-to-wall measurement |
|
|
|
|
||
|
Baseline |
2.0 (0.0) |
5.7 (0.0) |
- |
- |
|
|
Week 12 |
2.1 (0.0) |
4.9 (0.0) |
16.7 (8.3) |
-14.5 (-6.3) |
0.0634 |
|
Week 16 |
2.7 (0.0) |
4.7 (0.0) |
84.1 (27.3) |
-30.5 (-25.0) |
0.0108 |
Physician
Global Assessments
The Physician Global Assessments done in this study indicated that etanercept recipients had greater improvement from baseline than did placebo. This treatment difference was statistically significant (Table 58).
Table 58 Other Endpoints: Physician
Global Assessment
Physician Global Assessment: Mean
(Median) Values % Change From Baseline to Week 16 |
|||||||
|
|
Actual values |
% change from baseline |
|
|||
|
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
|
Parameter |
n = 20 |
n = 20 |
n = 20 |
n = 20 |
P-value* |
||
Physician global assessment |
|
|
|||||
|
Baseline |
51.1 (48.0) |
56.6 (54.5) |
- |
- |
- |
|
|
Week 12 |
52.1 (59.0) |
27.5 (30.0) |
3.3 (0.0) |
-53.8 (-58.2) |
<0.0001 |
|
|
Week 16 |
52.3 (55.5) |
26.2 (23.0) |
-0.7 (4.8) |
-55.7 (-66.7) |
<0.0001 |
|
Pain
Assessment, Dougados Spondylitis Functional Index and Krupp’s Fatigue Measure
The remaining three instruments
have been published in the medical literature as useful in the measurement of
Ankylosing Spondylitis disease activity and response to treatment (Table 69 and 70 Appendices
J and K). In this study, these
instruments were used in the secondary endpoint analysis to assess their
performance. As shown in (Table 59), in each of the three
instruments, etanercept achieved statistically higher response compared to
placebo.
Table 59 Other Endpoints: Pain Assessment, DSFI, Krupp’s
Fatigue Measure
Pain Assessment, DSFI, Krupp’s Fatigue
Measure: Mean (Median) Values and Percent Change From Baseline to Week 16 |
||||||
|
|
Actual values |
% change from baseline |
|||
|
Placebo |
Etanercept |
Placebo |
Etanercept |
|
|
n = 20 |
n = 20 |
n = 20 |
n = 20 |
P-value* |
||
Pain |
||||||
|
Baseline |
49.6 (49.0) |
58.3 (62.0) |
|
|
|
|
Week 12 |
45.2 (53.5) |
32.4 (29.5) |
-2.8 (-11.9) |
-42.4 (-44.4) |
0.0066 |
|
Week 16 |
43.6 (39.5) |
32.5 (23.5) |
-11.2 (-6.9) |
-42.5 (-52.6) |
0.0114 |
DSFI |
||||||
|
Baseline |
13.1 (12.0) |
16.6 (18.0) |
|
|
|
|
Week 12 |
11.6 (9.5) |
11.7 (10.5) |
-10.3 (-4.2) |
-27.0 (-35.6) |
0.1594 |
|
Week 16 |
12.0 (10.0) |
9.9 (8.0) |
-3.9 (0.0) |
-37.5 (-46.7) |
0.0360 |
Krupp's fatigue measure |
||||||
|
Baseline |
4.3 (4.6) |
4.6 (5.0) |
|
|
|
|
Week 12 |
4.1 (3.7) |
4.1 (4.2) |
-1.3 (-6.0) |
-5.2 (-15.0) |
0.1478 |
|
Week 16 |
4.5 (4.4) |
4.0 (4.2) |
8.2 (3.5) |
-5.7 (-17.8) |
0.0036 |
Conclusions
Efficacy
In study 016.0626, etanercept 25mg sc biw was statistically significant to placebo in achieving a 20% improvement in 3 of 5 pre-specified response criteria at 16 weeks. When ASAS Working Group Response Criteria are applied in ad hoc analysis, etanercept was statistically superior to placebo in the achievement of the ASAS 20 response at 16 weeks. Although the 50% response level achieves statistical significance using the pre-specified response criteria, neither the ASAS 50 nor the ASAS 70 achieves statistically significant improvement in this study. 4 of the 5 components of the pre-specified response criteria showed improvement, further supporting the superiority of etanercept over placebo. Swollen peripheral joint improvement while numerically higher in the etanercept recipients fails to reach statistical significance. In this 16-week study, all three spinal mobility parameters showed statistically significant improvement with etanercept compared to placebo. This study examined the performance of three additional instruments that have been published in the medical literature as useful in the measurement of Ankylosing Spondylitis disease activity and response to treatment.
The Spinal Pain Assessment, the Dougados Spondylitis Functional Index, and the Krupp’s Fatigue Measurement independently indicated statistically significant improvement with etanercept.
Overall
Summary of Efficacy
In all three studies that are reviewed in this document etanercept 25mg sc biw was superior to placebo in the achievement of pre-specified response criteria. For the two phase 3 studies, those pre-specified criteria were the ASAS Working Group Response Criteria. For the earlier phase 2 study, the pre-specified criteria were different but the result again demonstrated etanercept’s superiority over placebo. In that phase 2 study, an ad hoc analysis using the ASAS Response Criteria, which were of necessity modified to accommodate those criteria, the results resemble those seen in the phase 3 studies.
Swollen peripheral joint assessment was one of the components of the phase response criteria for the 2 study and one in which etanercept superiority over placebo did not achieve statistical significance. Swollen and tender peripheral joint measurements were part of the other endpoints of the phase 3 studies. Only in study 016.0037 was statistically greater improvement demonstrated with etanercept and then only in tender joints but not swollen joints.
In all three studies, spinal mobility was a separately measured domain. The results of these measurements varied between studies with statistical significant improvement in all three components of spinal mobility seen in study 016.0037 but for only one component (modified Schober’s test) in study 47687 and for two components in 016.0626. For the two studies with treatment beyond 12 weeks, the improvement in spinal mobility parameters appeared to increase with longer duration of etanercept treatment. The two studies that showed inconsistent results for the different measurements of spinal mobility were both smaller and of shorter duration than study 016.0037, where improvement was seen in all these measures.
Acute phase reactants were also separately measured in all three studies and in all three studies, ESR and CRP determinations supported greater improvement with etanercept than placebo.
Exploratory Analyses were performed on the largest of the three studies, study 016.0037. DCART 20 and DCART 40 that have been proposed as potentially useful in the assessment of short-term benefit in Ankylosing Spondylitis were performed and etanercept was demonstrated to be statistically superior to placebo in both. All subgroup analyses performed indicated that etanercept was superior to placebo although increasing age, female gender, being HLA-B27 negative and having concomitant psoriasis all appeared to be associated with lower response rates. The use of DMARDS did not appear to have an impact upon the treatment difference.
Overall Summary of Safety
In all three studies, injection site reactions and
infections were consistently more common in the etanercept recipients versus
the placebo recipients. The infections
were mostly of Grade 1 and 2 intensity and infections of the upper airways and
mouth appeared to be largely responsible for the higher incidence of infections
in the etanercept recipients. In study
016.0037, a notable difference between safety withdrawals for etanercept and
placebo were noted. Of the 7 safety withdrawals in that study, 4 were for bowel
symptoms. Of the 4 withdrawals for bowel symptoms, 3 were for symptoms
consistent with inflammatory bowel disease. Two of these were diagnosed as
inflammatory bowel of which one represented a recurrence and the other a newly
diagnosed inflammatory bowel disease. The significance of this is unknown.
APPENDICES
Table
60 Appendix A Modified New York Criteria for Ankylosing Spondylitis
|
Modified New York Criteria for Ankylosing
Spondylitis |
1. |
Low-back pain of at least 3 months duration improved by exercise and not relieved by rest. |
2. |
Limitation of lumbar spine in sagittal and frontal planes. |
3. |
Chest expansion decreased relative to normal values for age and sex. |
4. |
Bilateral sacroiliitis, grade 2-4 (see Appendix J: Stoke). |
5. |
Unilateral sacroiliitis, grade 3-4 (see Appendix J: Stoke). |
Definite AS if unilateral grade 3 or 4 or bilateral grade 2-4 sacroiliitis and any clinical criteria. |
Table
61 Appendix B : Stoke Ankylosing Spondylitis Spine Score
|
Stoke Ankylosing Spondylitis Spine Score |
0 |
Normal |
1 |
Blurring of joint margin |
2 |
1 + periarticular sclerosis or pseudo-widening |
3 |
2 + erosions or partial bony bridging |
4 |
Complete ankylosis |
Table 62 APPENDIX C. BATH
ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX
Please draw a mark on each line below to
indicate your level of ability with each of the
following activities during the last week.
(An aid is a piece of equipment which helps you
to perform an action or movement.)
1) Putting on your socks or tights without
help or aids (e.g. sock aid)
EASY____________________________________________________________
IMPOSSIBLE
2) Bending forward from the waist to pick up
a pen from the floor without an aid
EASY ___________________________________________________________
IMPOSSIBLE
3) Reaching up to a high shelf without help
or aids (e.g. helping hand)
EASY____________________________________________________________
IMPOSSIBLE
4) Getting up out of an armless dining room
chair without using your hands or any other
help
EASY________________________________________________________ IMPOSSIBLE
5) Getting up off the floor without help from
lying on your back
EASY____________________________________________________________
IMPOSSIBLE
6) Standing unsupported for 10 minutes
without discomfort
EASY____________________________________________________________
IMPOSSIBLE
7) Climbing 12-15 steps without using a
handrail or walking aid. One foot on each step
EASY____________________________________________________________
IMPOSSIBLE
8) Looking over your shoulder without turning
your body
EASY____________________________________________________________
IMPOSSIBLE
9) Doing physically demanding activities
(e.g. physiotherapy exercises, gardening or
sports) EASY______________________________________________________
IMPOSSIBLE
10) Doing a full day's activities whether it
be at home or at work
EASY____________________________________________________________
IMPOSSIBLE
Table 63 APPENDIX D. BATH ANKYLOSING
SPONDYLITIS DISEASE ACTIVITY
INDEX
Please place a mark on each line below to
indicate your answer to each question, relating
to the past week.
1) How would you describe the overall level
of fatigue/tiredness you have experienced?
NONE________________________________________________________
VERY SEVERE
2) How would describe the overall level of AS
neck, back or hip pain you have had?
NONE ________________________________________________________VERY
SEVERE
3) How would you describe the overall level
of pain/swelling in joints other than neck,
back or hips you have had?
NONE________________________________________________________
VERY SEVERE
4) How would you describe the overall level
of discomfort you have had from any areas
tender to touch or pressure?
NONE________________________________________________________
VERY SEVERE
5) How would you describe the overall level
of morning stiffness you have had from the
time you wake up?
NONE________________________________________________________
VERY SEVERE
6) How long does your morning stiffness last
from the time you wake up?
Table 64
APPENDIX E. VISUAL ANALOG SCALE: PHYSICIAN GLOBAL
ASSESSMENT
Please place a vertical mark on the line
below to indicate your overall assessment of the
patient’s disease activity during the last
week.
NONE______________________________________________________
SEVERE
Table 65 APPENDIX F. VISUAL
ANALOG SCALE: PATIENT GLOBAL ASSESSMENT
Please place a vertical mark on the line
below to indicate your overall assessment of your
disease activity during the last week.
NONE_______________________________________________________
SEVERE
Table 66 APPENDIX G. VISUAL
ANALOG SCALES: NOCTURNAL AND TOTAL BACK
PAIN
Part A: Nocturnal Back Pain
Instructions: Based on your assessment, place
one vertical line on the scale below from
no pain to most severe pain.
What is the amount of back pain at night that
you experienced during the last week?
NO PAIN_________________________________________________
MOST SEVERE PAIN
Part B: Total Back Pain
Instructions: Based on your assessment, place
one vertical line on the scale below from
no pain to most severe pain.
What is the amount of back pain at any time
that you experienced during the last week?
NO
PAIN_________________________________________________ MOST SEVERE PAIN
Table 67
APPENDIX H. PROCEDURES FOR SPINAL MOBILITY TESTING
1.
Chest Expansion Score:
Measured circumferentially at nipple line in
centimetres and recorded at maximal
inspiration and maximal expiration. Record
two tries, with the final score being the one
with the larger difference between
inspiration and expiration.
Inspiration (cm) Expiration (cm) Difference
(cm)
First Try
Second Try
2.
Schober’s Test:
With the patient standing erect, place a mark
in the midpoint of a line that joins the
posterior superior iliac spines. Place
another mark 10 cm above the first. Then, have the
patient maximally bend forward, keeping the
knees fully extended. With the spine in full
flexion, remeasure the distance between the
two marks in centimetres.
3.
Occiput-to-Wall Measurement:
Place the patient standing with his/her back
against the wall and measure the distance
between the occiput and wall. The better
(lesser distance) in centimetres will be recorded
as the final value.
First Try: ______ Second Try: ______
Table 68 APPENDIX I. EVALUATION
OF HIP INVOLVEMENT
R L
Does the patient have hip pain? Yes/No Yes/No
If yes: Medial/Lateral
Medial/Lateral
Does the patient have hip stiffness? Yes/No
Yes/No
Is range of motion painful? Yes/No Yes/No
Is range of motion limited? Yes/No Yes/No
Does the patient have trochanteric
tenderness? Yes/No Yes/No
Does the patient have antalgic gait? Yes/No
Yes/No
Table 69 Appendix J
Dougados Spondylitis Functional Index ~xr83i
Put on your shoes
Pull on trousers
Pull on a pullover
Get into a bathtub
Remain standing for 10 minutes
Climb 1 flight of stairs
Run
Sit down
Get up from a chair
Get into a car
Bend over to pick up an object
Crouch
Lie down
Turn in bed
Get out of bed
Sleep on your back
Sleep on your stomach
Do your job or housework
Cough or sneeze
Breath deeply
Total Score
Table 70 Appendix K Krupp Fatigue Severity Scale ~xr86i
Choose a number from 1 to 7 that
indicates your degree of agreement with each of the following
statements. One indicates strong disagreement and 7 indicates strong agreement.
1. My motivation is lower when I
am fatigued.
2. Exercise brings on my fatigue.
3. I am easily fatigued.
4. Fatigue interferes with my
physical functioning.
5. Fatigue causes frequent
problems for me.
6. My fatigue prevents sustained
physical functioning.
7. Fatigue interferes with
carrying out certain duties and responsibilities.
8. Fatigue is among my three most
disabling symptoms.
9. Fatigue interferes with my
work, family, or social life.